<!DOCTYPE html>
<html>
<head>
    <meta charset="utf-8" />
    <!-- Website Design By: www.happyworm.com -->
    <title>E Module</title>
    <!-- fonticon -->
    <link href="../common/css/font-awesome.css" rel="stylesheet" />
    <!-- textillate -->
    <link href="../common/css/animate.css" rel="stylesheet">
    <link href="../common/css/style.css" rel="stylesheet">
    <link href="../common/css/table.css" rel="stylesheet">
    <link href="../common/css/bluetable.css" rel="stylesheet">
    <!-- bootstrap -->
    <link rel="stylesheet" href="../common/css/bootstrap.min.css">
    <link rel="stylesheet" href="../common/css/bootstrap-theme.min.css">
    <link href="../common/css/sticky-footer.css" rel="stylesheet">
    <!-- slide bar -->
    <link href="../common/css/mbExtruder.css" media="all" rel="stylesheet" type="text/css">
    <!-- custom styles -->
    <link href="../common/css/common.css" media="all" rel="stylesheet" type="text/css">
    <!-- jquery Slider -->
    <link href="../common/css/simple-slider.css" rel="stylesheet" type="text/css" />
    <link href="../common/css/simple-slider-volume.css" rel="stylesheet" type="text/css" />
    <!-- tooltip -->
    <link href="../common/css/tipsy.css" rel="stylesheet" type="text/css" />
    <!-- image efect -->
    <link rel="stylesheet" href="../common/css/hoverEx.css" />
    <!-- jquery dropdown -->
    <link type="text/css" rel="stylesheet" href="../common/css/jquery.dropdown.css" />
    <!-- scripts-->
    <!-- Latest compiled and minified JavaScript -->

    <script type="text/javascript" src="../common/js/jquery-1.9.1.js"></script>

    <script type="text/javascript" src="../common/js/jquery-ui.js"></script>

    <script type="text/javascript" src="../common/js/jquery.dropdown.js"></script>

    <!-- simple slider -->

    <script src="../common/js/simple-slider.js"></script>

    <!-- bootstrap -->

    <script src="../common/js/bootstrap.min.js"></script>

    <!-- slide bar -->

    <script type="text/javascript" src="../common/js/jquery.hoverIntent.min.js"></script>

    <script type="text/javascript" src="../common/js/jquery.mb.flipText.js"></script>

    <script type="text/javascript" src="../common/js/mbExtruder.js"></script>

    <!-- textillate -->

    <script src="../common/js/jquery.fittext.js"></script>

    <script src="../common/js/jquery.lettering.js"></script>

    <script src="../common/js/jquery.textillate.js"></script>

    <!-- tooltip -->

    <script src="../common/js/jquery.tipsy.js"></script>

    <!-- course player -->

    <script src="../common/js/player/CoursePlayer.js"></script>

    <script src="../common/js/player/TrackerService.js"></script>

    <script src="../common/js/custom.js"></script>

    <script type="text/javascript">
    $(function () {
        $("#extruderLeft2").buildMbExtruder({
            position: "left",
            width: 200,
            positionFixed: false,
            top: 125,
            extruderOpacity: .8,
            onExtOpen: function () { },
            onExtContentLoad: function () { },
            onExtClose: function () { }
        });
    });

    function PlayEvents() {
    }
    PlayEvents.prototype.onAudioFailed = function () {
        alert("Failed to load audio.");
    }

    var coursePlayer = null;

    function Init() {
        coursePlayer = new CoursePlayer("moduleAudio", new PlayEvents());
        coursePlayer.initialize("Clinical_and_pathological_features_of_the_sALCL_subgroups_and_primary_cutaneous_ALCL.xml");
        coursePlayer.play();
    }

    function Next() {
        if (disableAll)
            return;
        if (coursePlayer.nextSlide())
            coursePlayer.play();
    }
    function Prev() {
        if (disableAll)
            return;
        if (coursePlayer.prevSlide())
            coursePlayer.play();
    }

    function play() {
        if (disableAll)
            return;

        if (!coursePlayer.getPlayerStatus()) {
            document.getElementById("toggelbutton").src = "../common/img/pauseBtn.png";
            coursePlayer.play();
        }
        else {

            document.getElementById("toggelbutton").src = "../common/img/playBtn.png";
            coursePlayer.pause();
        }
    }



        //]]>
    </script>
	
	<style type="text/css">
	.secondtoo tr:nth-child(2) td{
	background:-o-linear-gradient(bottom, #00717f 5%, #00718f 100%);	
	background:-webkit-gradient( linear, left top, left bottom, color-stop(0.05, #00717f), color-stop(1, #00718f) );
	background:-moz-linear-gradient( center top, #00717f 5%, #00718f 100% );
	filter:progid:DXImageTransform.Microsoft.gradient(startColorstr="#00717f", endColorstr="#00718f");	
	background: -o-linear-gradient(top,#00717f,00718f);

	background-color:#005fbf;
	border:0px solid #000000;
	text-align:center;
	border-width:0px 0px 1px 1px;
	font-size:14px;
	font-family:Verdana;
	font-weight:bold;
	color:#ffffff;
}
	</style>

</head>
<body style="overflow-x: hidden; font-family: Verdana" onload="createAttempt();">
    <div id="wrap" style="width: 1024px;">
        <div class="" style="height: 90px;">
            <div class="header-top">
            </div>
            <div class="header-body">
                <img src="../common/img/logo.png" class="logo" />
                <div class="header-help">
                    <div style="float: right">
                        <img class="effect" onmouseover="HideToolTip(this)" onclick="onclickPlaylistImg()"
                            data-toggle="tooltip" data-placement="left" title="Playlist" style="float: left;
                            opacity: 0.7; width: 36px; margin-top: 14px; margin-right: 8px;" src="../common/img/content.png" />
                        <img class="effect" onmouseover="HideToolTip(this)" data-horizontal-offset="-10"
                            data-dropdown="#dropdown-6" data-toggle="tooltip" data-placement="bottom" title="Reference"
                            style="float: left;" src="../common/img/smallicon1.png" />
                        <img class="effect" onmouseover="HideToolTip(this)"  onclick="onclickGlossaryImg()" data-toggle="tooltip" data-placement="customTooltip"
                            title="Glossary" style="float: left; margin-right: 40px;" src="../common/img/smallicon4.png" />
                        <img class="headerleftbg" src="../common/img/headerCorBg.png" />
                    </div>
                </div>
                <h4 id="slideTitle" class="module-title" style="margin-top: -5%; margin-left: 25%;
                    max-width: 50%;">
                </h4>
                <div id="dropdown-6" class="dropdown dropdown-tip dropdown-anchor-right has-icons">
                    <div class="dropdown-panel">
                    </div>
                </div>
            </div>
            <audio id="moduleAudio"></audio>
        </div>
        <div style="position: relative; height: 615px;">
            <!--<div id="extruderLeft2" class="a {title:'Slides\'s', url:'parts/extruderLeft.html'}">
                <div class="playlist" style="height: 615px;">
                    <div class="playlist-header"></div>
                    <div id="playlist" class="playlist-item">
                        <div class="list-items">title <span>0:00</span></div>
                    </div>
                    <div class="playlist-footer">
                        <p>Total Duration : <span id="totalDuration">00:00</span></p>
                    </div>
                </div>

            </div>-->
            <div class="slidePlayer">
                <div id="PlayListDiv" style="display: none;">
                    <div class="coursecontent" style="height: 600px; width: 100%;">
                        <div class="playlist-header">
                            <button type="button" class="header-close" onclick="onclickClosePlaylist()" style="float: right;">
                                Close</button>
                        </div>
                        <div id="playlist" class="playlist-item  style-5">
                            <div class="list-items">
                                title <span>0:00</span></div>
                        </div>
                        <div class="playlist-footer">
                            <p>
                                Total Duration : <span id="totalDuration">00:00</span></p>
                        </div>
                    </div>
                </div>
                <div id="GlossaryDiv" style="display: none;">
                    <div class="coursecontent" style="height: 600px; width: 100%;">
                        <div class="playlist-header">
                            <button type="button" class="header-close" onclick="onclickCloseglossary()" style="float: right;">Close</button>
                        </div>
                        <div id="Div2" class="playlist-item  style-5">
                            <div id="GlossaryTitle" class="GlossaryTitle style-5">
                                
                            </div> 
                             <div id="GlossaryData" class="GlossaryData style-5">
                               
                            </div>
                        </div>
                        <div class="playlist-footer">
                            
                        </div>
                    </div>
                </div>
              <div id="slide1" style="display: none;">
				
                    <!-- <div class="topic-bar">
                        <div id="topic-title">Title</div>
                    </div>-->
                    <!--Body -->
                    <div style="height: 550px;width: 100%;float: left;border: 2px solid rgba(127, 145, 145, 0.12);border-radius: 10px;background-color: rgba(255, 255, 255, 0.2);">
                        <div class="playBody">
                            <div class="fadeInDown" style="display: none;width:600px;margin-top: 45px;margin:0px auto;" id="s1img1">
                                <p class="breakout" style="font-size:20px;">
                                    Systemic Anaplastic Large Cell Lymphoma (sALCL)</p>
                            </div>
                        </div>
                    </div>
                </div>
				
				
				 <div id="slide1a" style="display: none;">
           

                    <div class="slidecontent" style="">
                        <div class="playBody">

                                <div id="bimg1" style="display:none;padding-left:20px;">
                                <img data-class="fadeInDown"  src="../common/img/bullet01.png" style=" width: 12px;
height: 12px;
float: left;
margin: 10px;
margin-top: 36px;" />
                                <p data-class="fadeInDown" style=" padding-top: 30px" >Material presented is for internal training purposes only</p>
                                 </div>
                              <div id="bimg2" style="display:none;padding-left:20px;">
                                <img data-class="fadeInDown"  src="../common/img/bullet01.png" style=" width: 12px; height: 12px; float: left; margin: 10px; margin-top: 5px;" />
                                <p data-class="fadeInDown" style="" >By the end of this module you should</p>
                            </div><br />
                                <div id="bimg3" style="display:none;padding-left:40px;">
                                <img data-class="fadeInDown"  src="../common/img/bullet01.png" style=" width: 12px; height: 12px; float: left; margin: 10px;margin-bottom: 30px;" />
                                <p data-class="fadeInDown" style="" >Be familiar with morphological features, epidemiology, and clinical features of systemic anaplastic large cell lymphoma</p>
                                <br />
                                    </div>
                                <div id="bimg4" style="display:none;padding-left:40px;">
                                <img data-class="fadeInDown"  src="../common/img/bullet01.png" style=" width: 12px; height: 12px; float: left; margin: 10px;margin-bottom: 30px;" />
                                <p data-class="fadeInDown" style="" >Be aware of prognosis and staging of treatment strategies recommended for systemic anaplastic large cell lymphoma</p>
                                <br />
                                    </div>
                                

                        </div>
                   </div>


                   
                    <div onclick="onclickShowTranscription(this);" id="stickyContent" style="display: none; position: absolute; right: 0; margin-top: 184px;">
                        <a href="#"><img src="../common/img/showTrans.png" /></a>
                    </div>
                    <div id="transcript-hide" style="display: none;">
                        <center> <button type="button" class="hidebutton" onclick="onclickHideTranscription(this);" > Hide Transcript</button></center>
                        <div class="transcript" style="">
                            <p>
                                This module is a part of an e-learning program which focuses on the different aspects of brentuximab vedotin, pivotal clinical trials with brentuximab vedotin, role and approval for use in certain patient populations which include; patients with relapsed or refractory Hodgkin’s lymphoma and patients with relapsed or refractory systemic anaplastic large-cell lymphoma. The material presented as part of this e-learning program is strictly for internal training purposes only.
                            </p>
                            <p>
                                 This module will enable you to get familiarized with the morphological features, epidemiology, and clinical features of systemic anaplastic large cell lymphoma. 
                            </p>
                            <p>
                               By the end of this module you should be aware of the prognosis and staging of systemic anaplastic large-cell lymphoma and be able to discuss treatment strategies recommended for systemic anaplastic large-cell lymphoma.
                            </p>
                            



                        </div>
                    </div>
                </div>
				
				
				
				
               <div id="slide2" style="display: none;">
                    <!--Body -->
                    <!--<div class="topic-bar">
                        <div id="topic-title">sALCL: Introduction</div>
                     </div>-->
                    <div class="slidecontent" style="">
                        <div class="playBody">
                            <br />
                            <div id="bimg1" style="display: none; padding-left: 20px;">
                                <img data-class="fadeInRight" src="../common/img/bullet01.png" style="width: 12px; height: 12px;
                                    float: left; margin: 10px;" />
                                <p data-class="fadeInRight" style="padding-left: 34px">
                                    ALCL is a subtype of mature T-cell and NK-cell neoplasms, which are a subset of
                                    non-Hodgkin’s lymphomas (NHLs)<sup>1,2</sup>
                                </p>
                                <br />
                            </div>
                            <div id="bimg2" style="display: none; padding-left: 20px;">
                                <img data-class="fadeInRight" src="../common/img/bullet01.png" style="width: 12px; height: 12px;
                                    float: left; margin: 10px;" />
                                <p data-class="fadeInRight" style="padding-left: 34px">
                                    ALCL was first described in 1985, as a Ki-1 (now commonly referred to as CD30) lymphoma,
                                    characterised by large pleomorphic cells expressing CD30, and with a tendency to
                                    invade lymph node sinuses<sup>3</sup></p>
                                <br />
                            </div>
                            <div id="bimg3" style="display: none; padding-left: 20px;">
                                <img data-class="fadeInRight" src="../common/img/bullet01.png" style="width: 12px; height: 12px;
                                    float: left; margin: 10px;" />
                                <p data-class="fadeInRight" style="padding-left: 34px">
                                    The current designation for this neoplasm is ALCL, per the 2008 World Health Organization
                                    (WHO) classification of lymphoid neoplasms<sup>1</sup><sup>,</sup><sup>4</sup></p>
                                <br />
                            </div>
                            <div id="bimg4" style="display: none; padding-left: 20px;">
                                <img data-class="fadeInRight" src="../common/img/bullet01.png" style="width: 12px; height: 12px;
                                    float: left; margin: 10px;" />
                                <p data-class="fadeInRightBig" style="padding-left: 34px">
                                    There are three distinct forms/types of ALCL<sup>1</sup><sup>,</sup><sup>2</sup></p>
                                <br />
                            </div>
                            <div id="bimg5" style="display: none; padding-left: 40px;">
                                <img data-class="fadeInRight" src="../common/img/bullet01.png" style="width: 12px; height: 12px;
                                    float: left; margin: 10px;" />
                                <p data-class="fadeInRightBig" style="padding-left: 30px;">
                                    Primary cutaneous ALCL</p>
                            </div>
                            <div id="bimg6" style="display: none; padding-left: 40px;">
                                <img data-class="fadeInRight" src="../common/img/bullet01.png" style="width: 12px; height: 12px;
                                    float: left; margin: 10px;" />
                                <p data-class="fadeInRightBig" style="padding-left: 30px;">
                                    Systemic ALK+ ALCL (sALCL)</p>
                            </div>
                            <div id="bimg7" style="display: none; padding-left: 41px;">
                                <img data-class="fadeInRight" src="../common/img/bullet01.png" style="width: 12px; height: 12px;
                                    float: left; margin: 10px;" />
                                <p data-class="fadeInRightBig" style="padding-left: 30px;">
                                    Systemic ALK- ALCL</p>
                            </div>
                        </div>
                    </div>
                    <!--Transcript -->
                    <div onclick="onclickShowTranscription(this);" id="stickyContent" style="display: none;
                        position: absolute; right: 0; margin-top: 184px;">
                        <a href="#">
                            <img src="../common/img/showTrans.png" /></a>
                    </div>
                    <div id="transcript-hide" style="display: none;">
                        <center>
                            <button type="button" class="hidebutton" onclick="onclickHideTranscription(this);">
                                Hide Transcript</button></center>
                        <div class="transcript" style="">
                            <p>
                                Anaplastic Large Cell Lymphoma (ALCL) is a subtype of mature T-cell and Natural
                                Killer (NK)-cell neoplasms, which are a subset of non-Hodgkin’s lymphomas (NHLs).<sup>1,2</sup></p>
                            <ul>
                                <li><span>T-cell lymphomas, so-called by their post-thymic origin, are a biologically
                                    diverse and uncommon group of diseases.<sup>1</sup> </span></li>
                                <li><span>Routine immunophenotyping and molecular diagnostics, coupled with disease-specific
                                    clinical and pathologic features led to the recognition of the full spectrum of
                                    T-cell neoplasms, which include ALCL,<sup>1</sup> a cytotoxic T-cell or null phenotype
                                    that is lacking expression of both T and B-cell markers.</span></li>
                            </ul>
                            <p>
                                ALCL was first described in 1985, as a Ki-1 (now commonly referred to as CD30) lymphoma,
                                characterised by large pleomorphic cells expressing CD30, and with a tendency to
                                invade lymph node sinuses.<sup>3</sup></p>
                            <p>
                                The current designation for this neoplasm is ALCL, per the 2008 World Health Organization
                                (WHO) classification of lymphoid neoplasms.<sup>1,4</sup></p>
                            <p>
                                There are three distinct forms/types of ALCL that have only recently been recognized.
                                <sup>1</sup><sup>,</sup><sup>2</sup> They are:</p>
                            <ul>
                                <li><span>Primary cutaneous ALCL.</span></li>
                                <li><span>Systemic ALK+ ALCL (sALCL), and</span></li>
                                <li><span>Systemic ALK- ALCL.</span></li>
                            </ul>
                        </div>
                    </div>
                    <div id="slide2ref" style="display: none;" class="slide2ref">
                        <b>References:</b><br />
                        <br />
                        1. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th Edition.
                        Lyon, France, IARC Press 2008.<br /><br />
                        2. NCCN Non-Hodgkin’s Lymphomas Version 1.2014: http://www.nccn.org/professionals
                        /physician_gls /f_guidelines.asp <br /><br />
                        3. Stein H, et al. Blood 1985;66:848–858. <br /><br />
                        4. Medeiros L and Elenitoba-Johnson K. Am J Clin Pathol 2007;127:707–722. <br /><br />
                    </div>
                </div>
                <!--slide 3 starting-->
                <div id="slide3" style="display: none;">
                    <!--Body -->
                    <!--<div class="topic-bar">
                        <div id="topic-title">Frequency of T-cell Lymphoma Subtypes: From the International PTCL Study</div>
                     </div>-->
                    <div class="slidecontent" style="">
                        <div style="">
                            
                            <center>
                            <div id="img8" style="padding-top: 20px;
                                display: none;" class="soft-embossed">
                                <img data-class="fadeInRight" src="img/1.png" />
                            </div>
                            <div id="bimg9" style="display: none;width:535px;">
                               <p data-class="fadeInRightBig" style="font-size:12px;">
                                    ALCL =anaplastic large cell lymphoma; ALK =anaplastic lymphoma kinase; NOS = not otherwise specified; PTCL = peripheral T-cell lymphoma; TCL = T-cell lymphoma</p>
                            </div>
                            </center>
                        </div>
                    </div>
                    <!--Transcript -->
                    <div onclick="onclickShowTranscription(this);" id="stickyContent" style="display: none;
                        position: absolute; right: 0; margin-top: 184px;">
                        <a href="#">
                            <img src="../common/img/showTrans.png" /></a>
                    </div>
                    <div id="transcript-hide" style="display: none;">
                        <center>
                            <button type="button" class="hidebutton" onclick="onclickHideTranscription(this);">
                                Hide Transcript</button></center>
                        <div class="transcript" style="">
                            <p>
                                A recent International Peripheral T-cell and Natural Killer/T-Cell Lymphoma Study,
                                involving 22 institutions in North America, Europe and Asia, provided data on the
                                distribution or frequency of different PTCL subtypes &#45; based on 1,314 cases
                                by a consensus diagnosis.<sup>1</sup></p>
                            <p>
                                Data from this study showed that the most common subtypes were: PTCL-Not Otherwise
                                Specified (NOS) (26%) and angioimmunoblastic TCL (AITL) (19%), followed by NK/T-cell,
                                Adult T-cell leukaemia/lymphoma (ATLL), and ALCL (all approximately 10%), as well
                                as enteropathy-type PTCL (5%).<sup>1</sup>  All of the other specific subtypes of
                                PTCL represented less than 2% of the total.<sup>1</sup></p>
                            <p>
                                If you look at the left side of the pie chart, you'll notice that ALK+ and ALK-
                                ALCL are listed separately.</p>
                        </div>
                    </div>
                    <div id="slide3ref" style="display: none;" class="slide3ref">
                        <b>References:</b><br />
                        <br />
                        1. Vose JM, et al. J Clin Oncol 2008;26:4124-4130.<br /><br />
                    </div>
                </div>
                <!--slide 3 ending-->
                <!--slide04 starting-->
                <div id="slide4" style="display: none;">
                    <!--Body -->
                    <!--<div class="topic-bar">
                        <div id="topic-title">sALCL: Clinical and Biological Features</div>
                     </div>-->
                    <div class="slidecontent" style="">
                        <div class="playBody">
                            <br />
                            <div id="bimg10" style="display: none; padding-left: 20px;">
                                <img data-class="fadeInRight" src="../common/img/bullet01.png" style="width: 12px; height: 12px;
                                    float: left; margin: 10px;" />
                                <p data-class="fadeInRight" style="padding-left: 34px">
                                    ALCL is a clinically and biologically heterogeneous disease<sup>1</sup>
                                </p>
                                <br />
                            </div>
                            <div id="bimg11" style="display: none; padding-left: 20px;">
                                <img data-class="fadeInRight" src="../common/img/bullet01.png" style="width: 12px; height: 12px;
                                    float: left; margin: 10px;" />
                                <p data-class="fadeInRight" style="padding-left: 34px">
                                    sALCL is a clinically aggressive, systemic lymphoma that primarily involves lymph
                                    nodes<sup>1</sup><sup>,</sup><sup>2</sup></p>
                                <br />
                            </div>
                            <div id="bimg12" style="display: none; padding-left: 20px;">
                                <img data-class="fadeInRight" src="../common/img/bullet01.png" style="width: 12px; height: 12px;
                                    float: left; margin: 10px;" />
                                <p data-class="fadeInRight" style="padding-left: 34px">
                                    Virtually all ALCL characteristically display strong, uniform, membranous and paranuclear
                                    staining for CD30<sup>3</sup></p>
                                <br />
                            </div>
                            <div id="bimg13" style="display: none; padding-left: 20px;">
                                <img data-class="fadeInRight" src="../common/img/bullet01.png" style="width: 12px; height: 12px;
                                    float: left; margin: 10px;" />
                                <p data-class="fadeInRight" style="padding-left: 34px">
                                    The recent WHO classification now recognises a subclassification of sALCL &#45;
                                    two subgroups, based on expression of the ALK protein<sup>3</sup><sup>,</sup><sup>4</sup></p>
                                <br />
                            </div>
                            <div id="bimg14" style="display: none; padding-left: 60px;">
                                <img data-class="fadeInRight" src="../common/img/bullet01.png" style="width: 12px; height: 12px;
                                    float: left; margin: 10px;" />
                                <p data-class="fadeInRightBig" style="padding-left: 30px;">
                                    Systemic ALK-1 expressing ALCL (ALK+)</p>
                            </div>
                            <div id="bimg15" style="display: none; padding-left: 60px;">
                                <img data-class="fadeInRight" src="../common/img/bullet01.png" style="width: 12px; height: 12px;
                                    float: left; margin: 10px;" />
                                <p data-class="fadeInRightBig" style="padding-left: 30px;">
                                    Systemic ALK-1 negative ALCL (ALK-); regarded as a provisional disease entity by
                                    the 2008 WHO classification<sup>4</sup></p>
                            </div>
                        </div>
                    </div>
                    <!--Transcript -->
                    <div onclick="onclickShowTranscription(this);" id="stickyContent" style="display: none;
                        position: absolute; right: 0; margin-top: 184px;">
                        <a href="#">
                            <img src="../common/img/showTrans.png" /></a>
                    </div>
                    <div id="transcript-hide" style="display: none;">
                        <center>
                            <button type="button" class="hidebutton" onclick="onclickHideTranscription(this);">
                                Hide Transcript</button></center>
                        <div class="transcript" style="">
                            <p>
                                ALCL is a clinically and biologically heterogeneous disease.<sup>1</sup></p>
                            <p>
                                Systemic ALCL (sALCL) is a clinically aggressive, systemic lymphoma that primarily
                                involves lymph nodes.<sup>1</sup><sup>,</sup><sup>2</sup></p>
                            <p>
                                Virtually all ALCL characteristically displays strong, uniform, membranous and paranuclear
                                staining for CD30.<sup>3</sup> </span></li>
                                <p>
                                    The recent WHO classification now recognises a subclassification of sALCL—two subgroups,
                                    based on expression of the ALK protein. <sup>3</sup><sup>,</sup><sup>4</sup></p>
                                <ul>
                                    <li><span>Systemic ALK-1 expressing ALCL (ALK+) and </span></li>
                                    <li><span>Systemic ALK-1 negative ALCL (ALK-); which is regarded as a provisional disease entity
                                        by the 2008 WHO classification.<sup>4</sup></span></li>
                                </ul>
                                <p>
                                    Of the two ALCL subgroups, neoplasms that aberrantly express ALK and others that
                                    do not, ALK+ ALCL represent approximately 50&#45;80% of all ALCLs. The remaining
                                    cases are ALK- ALCL.<sup>1</sup></p>
                                <p>
                                    ALK+ ALCL has become a relatively well-defined entity at the histologic, immunophenotypic,
                                    and molecular levels.<sup>1</sup></p>
                                <p>
                                    There is currently no clear consensus regarding ALK- ALCL, although the predominant
                                    opinion expressed is that these neoplasms are not a distinct entity at the immunophenotypic
                                    or molecular level.<sup>1</sup></p>
                                <p>
                                    Emerging data indicate that ALK- ALCL are more aggressive neoplasms with poorer
                                    outcomes compared to those in patients with ALK+ ALCL.<sup>2</sup></p>
                        </div>
                    </div>
                    <div id="slide4ref" style="display: none;" class="slide4ref">
                        <b>References:</b><br />
                        <br />
                        1. Medeiros L and Elenitoba-Johnson K. Am J Clin Pathol 2007;127:707–722.<br />
                        <br />
                        2. Fornari A, et al. Hem Oncol 2009;27:161–170.<br /><br />
                        3. Falini B, et al. Blood 1999;93: 2697–2706.<br /><br />
                      
                        4. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th Edition. Lyon, France, IARC Press 2008.<br /><br />
                    </div>
                </div>
                <!--slide04 ending-->
                <!--slide 5 starting-->
                <div id="slide5" style="display: none;">
                    <!--Body -->
                    <!--<div class="topic-bar">
                        <div id="topic-title">sALCL: Incidence and Epidemiology</div>
                     </div>-->
                    <div class="slidecontent" style="">
                        <div class="playBody">
                            <br />
                            <div id="bimg16" style="display: none; padding-left: 20px;">
                                <img data-class="fadeInRight" src="../common/img/bullet01.png" style="width: 12px; height: 12px;
                                    float: left; margin: 10px;" />
                                <p data-class="fadeInRight" style="padding-left: 34px">
                                    sALCL is an uncommon type of NHL
                                </p>
                                <br />
                            </div>
                            <div id="bimg17" style="display: none; padding-left: 40px;">
                                <img data-class="fadeInRight" src="../common/img/bullet01.png" style="width: 12px; height: 12px;
                                    float: left; margin: 10px;" />
                                <p data-class="fadeInRightBig" style="padding-left: 30px;">
                                    2&#45;8% of all NHLs in adults, and 10&#45;30% of all NHLs in children<sup>1-3</sup></p>
                            </div>
                            <div id="bimg18" style="display: none; padding-left: 40px;">
                                <img data-class="fadeInRight" src="../common/img/bullet01.png" style="width: 12px; height: 12px;
                                    float: left; margin: 10px;" />
                                <p data-class="fadeInRightBig" style="padding-left: 30px;">
                                    Estimated sALCL incidence: approximately 5,000 adults/year and 20,000 children/year
                                    in the WHO Europe region<sup>4</sup></p>
                            </div>
                            <div id="bimg19" style="display: none; padding-left: 40px;">
                                <img data-class="fadeInRight" src="../common/img/bullet01.png" style="width: 12px; height: 12px;
                                    float: left; margin: 10px;" />
                                <p data-class="fadeInRightBig" style="padding-left: 30px;">
                                    Estimated sALCL mortality: approximately 2,000 adults/year and 8,000 children/year
                                    in the WHO Europe region<sup>4</sup></p>
                            </div>
                            <div id="bimg20" style="display: none; padding-left: 40px;">
                                <img data-class="fadeInRight" src="../common/img/bullet01.png" style="width: 12px; height: 12px;
                                    float: left; margin: 10px;" />
                                <p data-class="fadeInRightBig" style="padding-left: 30px;">
                                    In a cohort analysis of about 300 patients with PTCL, sALCL accounts for approximately
                                    12% of all subtypes: ALK+ (6.6%), and ALK- (5.5%)<sup>5</sup></p>
                            </div>
                            <div id="bimg21" style="display: none; padding-left: 40px;">
                                <img data-class="fadeInRight" src="../common/img/bullet01.png" style="width: 12px; height: 12px;
                                    float: left; margin: 10px;" />
                                <p data-class="fadeInRightBig" style="padding-left: 30px;">
                                    In the International Peripheral T-cell Lymphoma Project, the distribution of sALCL
                                    differed by geographic region<sup>5</sup>
                                </p>
                            </div>
                            <div>
                            <center>
                                <table class="leftbluetable secondtoo" cellspacing="5" cellpadding="3" border="0" class="slide11table"
                                    id="table1" style=" width: 512px;
                                    display: none;">
                                    <tr>
                                        <td colspan="4" style="border-bottom:1px solid black;">
                                            Distribution %</td>
                                    </tr>
                                      <tr>
                                        <td>
                                            ALCL</td>
                                        <td>
                                            North America</td>
                                        <td>
                                            Europe</td>
                                        <td>
                                            Asia</td>
                                    </tr>
                                    <tr>
                                        <td style="text-align: left;">
                                            ALK+</td>
                                        <td style="text-align: left;">
                                            16.0</td>
                                        <td style="text-align: left;">
                                            6.4</td>
                                        <td style="text-align: left;">
                                            3.2</td>
                                    </tr>
                                    <tr>
                                        <td style="text-align: left;">
                                            ALK-</td>
                                        <td style="text-align: left;">
                                            7.8</td>
                                        <td style="text-align: left;">
                                            9.4</td>
                                        <td style="text-align: left;">
                                            2.6</td>
                                    </tr>
                                </table>
                                </center>
                            </div>
                        </div>
                    </div>
                    <!--Transcript -->
                    <div onclick="onclickShowTranscription(this);" id="stickyContent" style="display: none;
                        position: absolute; right: 0; margin-top: 184px;">
                        <a href="#">
                            <img src="../common/img/showTrans.png" /></a>
                    </div>
                    <div id="transcript-hide" style="display: none;">
                        <center>
                            <button type="button" class="hidebutton" onclick="onclickHideTranscription(this);">
                                Hide Transcript</button></center>
                        <div class="transcript" style="">
                            <p>
                                sALCL is an uncommon type of NHL.</p>
                            <p>
                                It accounts for 2-8% of all NHLs in adults, and 10-30% of all NHLs in children.<sup>1</sup><sup>-</sup><sup>3</sup></p>
                            <p>
                                The incidence and mortality of sALCL was estimated using latest available data from
                                the WHO (numbers of cases of NHL in the WHO Europe region) and the median % of all
                                NHLs in adults (5%) and children (20%):<sup>1</sup><sup>-</sup><sup>4</sup></p>
                            <ul>
                                <li><span>In the WHO Europe region, the estimated incidence of sALCL is approximately
                                    5,000 adults/year and 20,000 children/year<sup>4</sup> and the estimated mortality
                                    is approximately 2,000 adults/year and 8,000 children/year.<sup>4</sup></span></li>
                            </ul>
                            <p>
                                In a cohort analysis of about 300 patients with PTCL, sALCL accounts for approximately
                                12% of all subtypes: ALK+ (6.6%), and ALK- (5.5%).<sup>5</sup></p>
                            <p>
                                In the International Peripheral T-cell Lymphoma Project, the distribution of sALCL
                                differed by geographic region:<sup>5</sup></p>
                            <ul>
                                <li><span>sALCL appears to be relatively uncommon in the Asian population, and more
                                    common in Western countries.<sup>5</sup></span></li>
                                <li><span>ALK+ ALCL is more common than ALK- ALCL in North America but appears to be
                                    slightly less common than ALK- ALCL in Europe, whereas the frequency of the two
                                    subgroups in Asia is similar.<sup>5</sup></span></li>
                            </ul>
                        </div>
                    </div>
                    <div id="slide5ref" style="display: none;" class="slide5ref">
                        <b>References:</b><br />
                        <br />
                        1. GLOBOCAN 2008 (IARC) WHO Europe data accessed from http://globocan.iarc.fr/.
                        <br />
                        <br />
                        2. Non-Hodgkin’s Lymphoma Classification Project. Blood 1997;89:3909–3918.
                        <br />
                        <br />
                        3. Stein H,et al. Blood 2000;96:3681–3695.
                        <br />
                        <br />
                        4. Fornarni A, et al. Hematological Oncology 2009;27:161–170.<br />
                        <br />
                        5. Vose JM, et al. J Clin Oncol 2008;26:4124-4130.<br /><br />
                    </div>
                </div>
                <!--slide 5 ending-->
           
                <!--slide 6 starting-->
                <div id="slide6" style="display: none;">
                    <!--Body -->
                    <!--<div class="topic-bar">
                        <div id="topic-title">sALCL: Demographics, Aetiology and Potential Risk Factors</div>
                     </div>-->
                    <div class="slidecontent" style="">
                        <div class="playBody">
                            <br />
                            <div id="bimg22" style="display: none; padding-left: 20px;">
                                <img data-class="fadeInRight" src="../common/img/bullet01.png" style="width: 12px; height: 12px;
                                    float: left; margin: 10px;" />
                                <p data-class="fadeInRight" style="padding-left: 34px">
                                    There is a bimodal age distribution by subgroup and sALCL is more common in men
                                    versus women</p>
                            </div>
                            <div id="bimga" style="float: right; width: 60%; padding-top: 14px; padding-right: 31px;
                                display: none;" class="soft-embossed">
                                <img data-class="fadeInRight" src="img/2graph.png" />
                            </div>
                            <div id="bimg23" style="display: none; padding-left: 40px; padding-top: 19px;">
                                <img data-class="fadeInRight" src="../common/img/bullet01.png" style="width: 12px; height: 12px;
                                    float: left; margin: 10px;" />
                                <p data-class="fadeInRightBig" style="padding-left: 30px;">
                                    ALK+ is most common
                                    <br />
                                    in children and young
                                    <br />
                                    adults<sup>1</sup><sup>-</sup><sup>4</sup></p>
                            </div>
                            <div id="bimg24" style="display: none; padding-left: 40px;">
                                <img data-class="fadeInRight" src="../common/img/bullet01.png" style="width: 12px; height: 12px;
                                    float: left; margin: 10px;" />
                                <p data-class="fadeInRightBig" style="padding-left: 30px;">
                                    ALK- is more common
                                    <br />
                                    in older patients
                                    <br />
                                    (>50 years)<sup>3</sup><sup>,</sup><sup>4</sup></p>
                            </div>
                            <div id="bimg25" style="display: none; padding-left: 20px; padding-top: 41px;">
                                <img data-class="fadeInRight" src="../common/img/bullet01.png" style="width: 12px; height: 12px;
                                    float: left; margin: 10px;" />
                                <p data-class="fadeInRight" style="padding-left: 34px">
                                    Aetiology of ALCL is<br />
                                    unknown; some potential risk
                                    <br />
                                    factors for NHL include:
                                </p>
                            </div>
                            <div id="bimg26" style="display: none; padding-left: 40px; padding-top: 15px;">
                                <img data-class="fadeInRight" src="../common/img/bullet01.png" style="width: 12px; height: 12px;
                                    float: left; margin: 10px;" />
                                <p data-class="fadeInRightBig" style="padding-left: 30px;">
                                    Family history of haematopoietic malignancies<sup>5</sup></p>
                            </div>
                            <div id="bimg27" style="display: none; padding-left: 40px;">
                                <img data-class="fadeInRight" src="../common/img/bullet01.png" style="width: 12px; height: 12px;
                                    float: left; margin: 10px;" />
                                <p data-class="fadeInRightBig" style="padding-left: 30px;">
                                    Immunosuppression, immunodeficiencies, autoimmune disease, and environmental factors<sup>6</sup></p>
                            </div>
                        </div>
                    </div>
                    <!--Transcript -->
                    <div onclick="onclickShowTranscription(this);" id="stickyContent" style="display: none;
                        position: absolute; right: 0; margin-top: 184px;">
                        <a href="#">
                            <img src="../common/img/showTrans.png" /></a>
                    </div>
                    <div id="transcript-hide" style="display: none;">
                        <center>
                            <button type="button" class="hidebutton" onclick="onclickHideTranscription(this);">
                                Hide Transcript</button></center>
                        <div class="transcript" style="">
                            <p>
                                sALCL occurs more frequently in children compared with adults.<sup>1</sup></p>
                            <p>
                                There is a bimodal age distribution by subgroup and sALCL is more common in men
                                versus women:</p>
                            <ul>
                                <li><span>ALK+ is most common in children and young adults.<sup>1</sup><sup>-</sup><sup>4</sup> It
                                    occurs mainly in the first three decades of life with male predominance being particularly
                                    striking in the second and third decades of life.<sup>1</sup></span></li>
                                <li><span>ALK- is more common in older patients (>50 years).<sup>3</sup><sup>,</sup><sup>4</sup></span></li>
                            </ul>
                            <p>
                                The aetiology of ALCL is unknown, but some potential risk factors for NHL include:
                            </p>
                            <ul>
                                <li><span>Family history of haematopoietic malignancies.<sup>5</sup></span></li>
                                <p style="padding-left: 20px;">
                                    <li><span>NHL confers a consistently stronger familial association among men than women,
                                        and NHL risk was highest among individuals who reported a brother with NHL.<sup>2</sup></span></li>
                                </p>
                            </ul>
                            <p>
                                Immunosuppression, immunodeficiencies, autoimmune disease, and environmental factors:<sup>6</sup></p>
                            <ul>
                                <li><span>Pathogens linked to the risk of lymphoma include the Epstein-Barr virus (EBV),
                                    however, EBV infection of the tumour cells in ALCL is rare or absent.<sup>1</sup><sup>,</sup><sup>3</sup></span></li>
                                <li><span>Chemicals that have been implicated in lymphomagenesis include agricultural
                                    herbicides and insecticides and hair dyes.<sup>3</sup></span></li>
                            </ul>
                        </div>
                    </div>
                    <div id="slide6ref" style="display: none;" class="slide6ref">
                        <b>References:</b><br />
                        <br />
                        1. Falini B, et al. Blood 1999;93:2697–2706.<br />
                        <br />
                        2. Medeiros and Elenitoba-Johnson. Am J Clin Pathol 2007;127:707–722.<br />
                        <br />
                        3. Savage K, et al. Blood Reviews 2007;21:201–216.<br />
                        <br />
                        4. Schmitz N, et al. Blood 2010;116:3418–3425.<br />
                        <br />
                        5. Wang S, et al. Blood 2007;109:34793488.<br />
                        <br />
                        6. Fisher S and Fisher R. Oncogene 2004;23:65234.<br /><br />
                    </div>
                </div>
                <!--slide 6 ending-->
                <!--slide 6 ending-->
                <div id="slide6a" style="display: none;">
                    <!-- <div class="topic-bar">
                        <div id="topic-title">HL: survival rates</div>
                    </div>-->
                    <!--Body -->
                    <div class="slidecontent" style="">
                        <div class="playBody">
                            <div style="padding-left: 20px">
                                <br />
                                <p data-class="fadeInDown" style="display: none;" id="s6atxt1">
                                    Potential risk factors for NHL include
                                </p>
                                <br />
                                <input type="hidden" id="Answer" value="4" qid="1" />
                                <input type="hidden" id="Percentage" value="50" />
                                <div id="radio1" style="padding: 10px 25px 10px 10px; display: none;">
                                    <input name="ratio1" value="1" type="radio" style="width: 2em; height: 1.5em; float: left;" />
                                    <p data-class="fadeInRight" style="padding-left: 55px;">
                                         Family history of haematopoietic malignancies
                                    </p>
                                </div>
                                <div id="radio2" style="padding: 10px 25px 10px 10px; display: none;">
                                    <input name="ratio1" value="2" type="radio" style="width: 2em; height: 1.5em; float: left;" />
                                    <p data-class="fadeInRight" style="padding-left: 55px;">
                                         Autoimmune disease, immunosuppression and immunodeficiencies</p>
                                </div>
                                <div id="radio3" style="padding: 10px 25px 10px 10px; display: none;">
                                    <input name="ratio1" value="3" type="radio" style="width: 2em; height: 1.5em; float: left;" />
                                    <p data-class="fadeInRight" style="padding-left: 55px;">
                                         Environmental factors</p>
                                </div>
                                <div id="radio4" style="padding: 10px 25px 10px 10px; display: none;">
                                    <input name="ratio1" value="4" type="radio" style="width: 2em; height: 1.5em; float: left;" />
                                    <p data-class="fadeInRight" style="padding-left: 55px;">
                                         All of the above</p>
                                </div>
                                
                                <div style="margin-left:470px;">
                                    <div>
                                        <input id="s6aimag9" onclick="onclickAnswer(this);" type="button" class="btn btn-primary" value="Submit"
                                            style="width: 100px; margin-right: 25px; display: none" />
                                    </div>
                                    <br />
                                </div>
                            </div>

                        </div>
                    </div>
                    <!--Transcript -->
                    <div onclick="onclickShowTranscription(this);" id="stickyContent" style="display: none;
                        position: absolute; right: 0; margin-top: 184px;">
                        <a href="#">
                            <img src="../common/img/showTrans.png" /></a>
                    </div>
                    <div id="transcript-hide" style="display: none;">
                        <center>
                            <button type="button" class="hidebutton" onclick="onclickHideTranscription(this);">
                                Hide Transcript</button></center>
                        <div class="transcript">
                            <br />
                            Please take a moment to answer a question. Please select the best answer and click submit to continue
                        </div>
                    </div>
                    <div id="slide6aref" style="display: none;" class="slide6aref">
                        <b>References:</b><br />
                        <br />
                        Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed
                        or Refractory Hodgkin’s Lymphoma. Younes et al. Journal Of Clinical Oncology. June
                        2012.
                    </div>
                </div>
                <!--slide 6a ending-->
                <!--slide 7 starting-->
                <div id="slide7" style="display: none;">
                    <!--Body -->
                    <!--<div class="topic-bar">
                        <div id="topic-title">sALCL: Clinical Presentation and Symptoms</div>
                     </div>-->
                    <div class="slidecontent" style="">
                        <div class="playBody">
                            <br />
                            <div id="bimg29" style="display: none; padding-left: 20px;">
                                <img data-class="fadeInRight" src="../common/img/bullet01.png" style="width: 12px; height: 12px;
                                    float: left; margin: 10px;" />
                                <p data-class="fadeInRight" style="padding-left: 34px">
                                    sALCL presents as an aggressive disease, primarily involving sinus areas of the
                                    lymph nodes<sup>1-3</sup>
                                </p>
                                <br />
                            </div>
                            <div id="bimg30" style="display: none; padding-left: 20px;">
                                <img data-class="fadeInRight" src="../common/img/bullet01.png" style="width: 12px; height: 12px;
                                    float: left; margin: 10px;" />
                                <p data-class="fadeInRight" style="padding-left: 34px">
                                    Extranodal involvement is frequent (60% of cases), with approximately 40% of patients
                                    with ALK+ sALCL showing two or more extranodal sites of the disease<sup>2</sup></p>
                                <br />
                            </div>
                            <div id="bimg31" style="display: none; padding-left: 20px;">
                                <img data-class="fadeInRight" src="../common/img/bullet01.png" style="width: 12px; height: 12px;
                                    float: left; margin: 10px;" />
                                <p data-class="fadeInRight" style="padding-left: 34px">
                                    Approximately two-thirds of patients with sALCL are known to have advanced-stage
                                    disease (ALK+, 65%; ALK-, 58%)<sup>3</sup></p>
                                <br />
                            </div>
                            <div id="bimg32" style="display: none; padding-left: 20px;">
                                <img data-class="fadeInRight" src="../common/img/bullet01.png" style="width: 12px; height: 12px;
                                    float: left; margin: 10px;" />
                                <p data-class="fadeInRightBig" style="padding-left: 34px">
                                    B symptoms are common (50&#45;75% of patients)<sup>4-6</sup></p>
                                <br />
                            </div>
                            <div id="bimg33" style="display: none; padding-left: 40px;">
                                <img data-class="fadeInRight" src="../common/img/bullet01.png" style="width: 12px; height: 12px;
                                    float: left; margin: 10px;" />
                                <p data-class="fadeInRightBig" style="padding-left: 30px;">
                                    Fever, weight loss, night sweats, fatigue and swollen lymph nodes</p><br />
                            </div>
                            <div id="bimg34" style="display: none; padding-left: 20px;">
                                <img data-class="fadeInRight" src="../common/img/bullet01.png" style="width: 12px; height: 12px;
                                    float: left; margin: 10px;" />
                                <p data-class="fadeInRightBig" style="padding-left: 34px">
                                    Clinical presentation in children is similar &#45; frequently with B symptoms (54%
                                    of patients).<sup>7</sup> Lymph node involvement is very common (92% of children),<sup>7</sup>with
                                    extranodal disease in approximately 68% of cases<sup>7</sup></p>
                                <br />
                            </div>
                        </div>
                    </div>
                    <!--Transcript -->
                    <div onclick="onclickShowTranscription(this);" id="stickyContent" style="display: none;
                        position: absolute; right: 0; margin-top: 184px;">
                        <a href="#">
                            <img src="../common/img/showTrans.png" /></a>
                    </div>
                    <div id="transcript-hide" style="display: none;">
                        <center>
                            <button type="button" class="hidebutton" onclick="onclickHideTranscription(this);">
                                Hide Transcript</button></center>
                        <div class="transcript" style="">
                            <p>
                                sALCL presents as an aggressive disease, primarily involving sinus areas of the
                                lymph nodes.<sup>1</sup><sup>-</sup><sup>3</sup></p>
                            <p>
                                Extranodal involvement is frequent (60% of cases), with approximately 40% of patients
                                with ALK+ sALCL showing two or more extranodal sites of the disease.<sup>2</sup>
                            </p>
                            <ul>
                                <li><span>The most frequent extranodal sites in ALK+ patients include: bone, subcutaneous
                                    tissue, bone marrow, and spleen.<sup>1</sup></span></li>
                                <li><span>The most frequent extranodal sites in ALK- patients include: skin, lung, liver,
                                    bone, and bone marrow.<sup>1</sup></span></li>
                                <li><span>The distribution of nodal disease is similar between ALK+ and ALK- patients,
                                    with 54% of ALK+ patients having nodal disease vs 49% of ALK- patients. </span></li>
                                <li><span>The distribution is also similar among patients with extranodal disease:
                                    20% of ALK+ patients have extranodal disease vs 21% of ALK- patients.<sup>1</sup></span></li>
                                <li><span>Involvement of the gut and central nervous system is rare.<sup>2</sup><sup>,</sup><sup>3</sup></span></li>
                                <li><span>In children, extranodal disease includes visceral involvement in 43% of cases
                                    and skin lesions in 26% of cases.<sup>3</sup></span></li>
                            </ul>
                            <p>
                                Approximately two-thirds of patients with sALCL are known to have advanced-stage
                                disease.<sup>3</sup></p>
                            <p>
                                B symptoms are common and experienced by 50-75% of patients.<sup>4</sup><sup>-</sup><sup>6</sup>
                                B symptoms include fever, weight loss, night sweats, fatigue and swollen lymph nodes.</p>
                            <p>
                                The clinical presentation in children is similar—54% of child patients experience
                                B symptoms.<sup>7</sup> Lymph node involvement is very common, occurring in 92% of
                                children,<sup>7</sup> with extranodal disease in approximately 68% of cases.<sup>7</sup></p>
                        </div>
                    </div>
                    <div id="slide7ref" style="display: none;" class="slide7ref">
                        <b>References:</b><br />
                        <br />
                       1.       Falini B, et al. Blood 1999;93:2697–2706.     <br />     <br />

2.       Stein H, et al. Blood 2000;96:3681–3695.     <br />     <br />

3.       Savage K, et al. Blood 2008;111:5496–5504.     <br />     <br />

4.       Armitage JO, Weisenburger DD. J Clin Oncol 1998;16:27802795.     <br />     <br />

5.       Schmitz N, et al. Blood 2010;116:3418–3425.     <br />     <br />

6.       WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th Edition. Lyon, France, IARC Press 2008.     <br />     <br />

7.       Le Delay M-C, et al. Blood 2008;111:1560–1566.     <br />     <br />
                    </div>
                </div>
                <!--slide 7 ending-->
                <!--slide 8 starting-->
                <div id="slide8" style="display: none;">
                    <!--Body -->
                    <!--<div class="topic-bar">
                        <div id="topic-title">sALCL: Diagnostic Tests and Procedures</div>
                     </div>-->
                    <div class="slidecontent" style="">
                        <div class="playBody">
                            <div id="bimg35" style="display: none; padding-left: 20px;">
                                <br />
                                <img data-class="fadeInRight" src="../common/img/bullet01.png" style="width: 12px; height: 12px;
                                    float: left; margin: 10px;" />
                                <p data-class="fadeInRight" style="padding-left: 34px">
                                    ALCL is currently diagnosed according to the WHO classification system and evaluations
                                    include:<sup>1</sup><sup>,</sup><sup>2</sup>
                                </p>
                                <br />
                            </div>
                            <div id="bimg36" style="display: none; padding-left: 40px;">
                                <img data-class="fadeInRight" src="../common/img/bullet01.png" style="width: 12px; height: 12px;
                                    float: left; margin: 10px;" />
                                <p data-class="fadeInRightBig" style="padding-left: 30px;">
                                    Full history, physical examination, and complete blood count with differential,
                                    and a metabolic panel including lactate dehydrogenase</p>
                            </div>
                            <div id="bimg37" style="display: none; padding-left: 40px;">
                                <img data-class="fadeInRight" src="../common/img/bullet01.png" style="width: 12px; height: 12px;
                                    float: left; margin: 10px;" />
                                <p data-class="fadeInRightBig" style="padding-left: 30px;">
                                    Lymph node excisional resection</p>
                            </div>
                            <div id="bimg38" style="display: none; padding-left: 40px;">
                                <img data-class="fadeInRight" src="../common/img/bullet01.png" style="width: 12px; height: 12px;
                                    float: left; margin: 10px;" />
                                <p data-class="fadeInRightBig" style="padding-left: 30px;">
                                    Skin biopsy for histology</p>
                            </div>
                            <div id="bimg39" style="display: none; padding-left: 40px;">
                                <img data-class="fadeInRight" src="../common/img/bullet01.png" style="width: 12px; height: 12px;
                                    float: left; margin: 10px;" />
                                <p data-class="fadeInRightBig" style="padding-left: 30px; "">
                                    Bone marrow biopsy and aspirate</p>
                            </div>
                            <div id="bimg40" style="display: none; padding-left: 40px;">
                                <img data-class="fadeInRight" src="../common/img/bullet01.png" style="width: 12px; height: 12px;
                                    float: left; margin: 10px;" />
                                <p data-class="fadeInRightBig" style="padding-left: 30px;">
                                    T-cell immunophenotyping; immunostaining for CD30</p>
                            </div>
                            <div id="bimg41" style="display: none; padding-left: 40px;">
                                <img data-class="fadeInRight" src="../common/img/bullet01.png" style="width: 12px; height: 12px;
                                    float: left; margin: 10px;" />
                                <p data-class="fadeInRightBig" style="padding-left: 30px;">
                                    Molecular genetic analysis to detect antigen receptor gene rearrangements; t(2;5)
                                    and variants</p>
                            </div>
                            <div id="bimg42" style="display: none; padding-left: 40px;">
                                <img data-class="fadeInRight" src="../common/img/bullet01.png" style="width: 12px; height: 12px;
                                    float: left; margin: 10px;" />
                                <p data-class="fadeInRightBig" style="padding-left: 30px;">
                                    Immunostaining with anti-ALK monoclonal antibodies</p>
                            </div>
                            <div id="bimg43" style="display: none; padding-left: 40px;">
                                <img data-class="fadeInRight" src="../common/img/bullet01.png" style="width: 12px; height: 12px;
                                    float: left; margin: 10px;" />
                                <p data-class="fadeInRightBig" style="padding-left: 30px;">
                                    Full body imaging (computed tomography) and (fluorodeoxyglucose positron emission
                                    tomography) scans</p>
                            </div>
                        </div>
                    </div>
                    <!--Transcript -->
                    <div onclick="onclickShowTranscription(this);" id="stickyContent" style="display: none;
                        position: absolute; right: 0; margin-top: 184px;">
                        <a href="#">
                            <img src="../common/img/showTrans.png" /></a>
                    </div>
                    <div id="transcript-hide" style="display: none;">
                        <center>
                            <button type="button" class="hidebutton" onclick="onclickHideTranscription(this);">
                                Hide Transcript</button></center>
                        <div class="transcript" style="">
                            <p>
                                ALCL is currently diagnosed according to the WHO classification system. The evaluations
                                include<sup>1</sup><sup>,</sup><sup>2</sup> a full history, physical examination,
                                and complete blood count with differential, and a metabolic panel including lactate
                                dehydrogenase (LDH).</p>
                            <p>
                                The workup also includes excision resection of the lymph node, skin biopsy for histology,
                                bone marrow biopsy and aspirate, T-cell immunophenotyping; immunostaining for CD30,
                                and molecular genetic analysis to detect antigen receptor gene rearrangements; specifically
                                translocation of genomic DNA from chromosomes 2 and 5 [t(2;5)] and variants.</p>
                            <p>
                                Additionally, the evaluation includes immunostaining with anti-ALK monoclonal antibodies
                                and/or reverse transcriptase polymerase chain reaction. These should be performed
                                to detect the upregulation of ALK for diagnostic and prognostic purposes.<sup>1</sup></p>
                            <p>
                                Finally, full body imaging computed tomography and fluorodeoxyglucose positron emission
                                tomography scans should be done for the presence/extent of systemic disease and
                                detection of extranodal disease.<sup>1</sup></p>
                            <p>
                                All histopathologic and molecular results should be correlated with clinical findings
                                and patients classified according to the WHO/European Organisation for Research
                                and Treatment of Cancer consensus classification.<sup>1</sup></p>
                        </div>
                    </div>
                    <div id="slide8ref" style="display: none;" class="slide8ref">
                        <b>References:</b><br /><br />
                        1. NCCN Non-Hodgkin’s Lymphomas Version1.2014 http://www.nccn.org/professionals
                        /physician_gls/f_guidelines.asp <br /><br />
                        2. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th Edition. Lyon, France, IARC Press 2008.<br /><br />

                    </div>
                </div>
                <!--slide 8 ending-->
                <!--slide 9 starting-->
                <div id="slide9" style="display: none;">
                    <!--Body -->
                    <!--<div class="topic-bar">
                        <div id="topic-title">sALCL: Diagnostic Immunophenotypic and Molecular Characteristics</div>
                     </div>-->
                    <div class="slidecontent" style="">
                        <div class="playBody">
                            <div id="bimg44" style="display: none; padding-left: 20px;">
                                <br />
                                <img data-class="fadeInRight" src="../common/img/bullet01.png" style="width: 12px; height: 12px;
                                    float: left; margin: 10px;" />
                                <p data-class="fadeInRight" style="padding-left: 34px">
                                    Immunophenotyping<sup>1</sup><sup>,</sup><sup>2</sup>
                                </p>
                                <br />
                            </div>
                            <div id="bimg45" style="display: none; padding-left: 40px;">
                                <img data-class="fadeInRight" src="../common/img/bullet01.png" style="width: 12px; height: 12px;
                                    float: left; margin: 10px;" />
                                <p data-class="fadeInRightBig" style="padding-left: 30px;">
                                    Immunopositivity for CD30</p>
                            </div>
                            <div id="bimg46" style="display: none; padding-left: 40px;">
                                <img data-class="fadeInRight" src="../common/img/bullet01.png" style="width: 12px; height: 12px;
                                    float: left; margin: 10px;" />
                                <p data-class="fadeInRightBig" style="padding-left: 30px;">
                                    Immunopositivity for ALK protein
                                </p>
                            </div>
                            <div id="bimg47" style="display: none; padding-left: 40px;">
                                <img data-class="fadeInRight" src="../common/img/bullet01.png" style="width: 12px; height: 12px;
                                    float: left; margin: 10px;" />
                                <p data-class="fadeInRightBig" style="padding-left: 30px;">
                                    Immunopositivity for epithelial membrane antigen (EMA)</p>
                            </div>
                            <br />
                            <div id="bimg48" style="display: none; padding-left: 20px;">
                                <img data-class="fadeInRight" src="../common/img/bullet01.png" style="width: 12px; height: 12px;
                                    float: left; margin: 10px;" />
                                <p data-class="fadeInRight" style="padding-left: 34px">
                                    Molecular characteristics
                                </p>
                                <br />
                            </div>
                            <div id="bimg49" style="display: none; padding-left: 40px;">
                                <img data-class="fadeInRight" src="../common/img/bullet01.png" style="width: 12px; height: 12px;
                                    float: left; margin: 10px;" />
                                <p data-class="fadeInRightBig" style="padding-left: 30px;">
                                    Common chromosomal translocation characterised by t(2;5)(p23;q35) that results in
                                    production of nucleophosmin (NPM)-ALK chimeric protein (also referred to as p80)<sup>3</sup><sup>,</sup><sup>4</sup></p>
                            </div>
                        </div>
                    </div>
                    <!--Transcript -->
                    <div onclick="onclickShowTranscription(this);" id="stickyContent" style="display: none;
                        position: absolute; right: 0; margin-top: 184px;">
                        <a href="#">
                            <img src="../common/img/showTrans.png" /></a>
                    </div>
                    <div id="transcript-hide" style="display: none;">
                        <center>
                            <button type="button" class="hidebutton" onclick="onclickHideTranscription(this);">
                                Hide Transcript</button></center>
                        <div class="transcript" style="">
                            <p>
                                Immunohistochemical screening of a large number of undifferentiated large cell malignancies
                                has revealed that the tumour cells of nearly all ALCL cases show a strong expression
                                of CD30 on the cell membrane and in the Golgi region. As a result, membrane-associated
                                expression of CD30 has been included in the definition of ALCL.<sup>1</sup></p>
                            <p>
                                To make a diagnosis under the present system of classification, the WHO requires,
                                in addition to the presence of ‘hallmark’ cells, immunopositivity for CD30,<sup>2</sup>
                                immunopositivity for ALK protein, and immunopositivity for epithelial membrane antigen
                                (EMA).</p>
                            <p>
                                Demonstration of the ALK protein by immunohistochemistry is usually sufficient to
                                establish the diagnosis of ALK+ ALCL in cases with typical morphology.<sup>3</sup></p>
                            <p>
                                sALCL also includes common chromosomal translocation characterised by t(2;5)(p23;q35)
                                that results in production of nucleophosmin (NPM)-ALK chimeric protein (also referred
                                to as p80).<sup>3,4</sup></p>
                            <p>
                                ALK fuses with nucleophosmin promoter in approximately 85% of cases of ALCL.<sup>4,5</sup></p>
                        </div>
                    </div>
                    <div id="slide9ref" style="display: none;" class="slide9ref">
                        <b>References:</b><br /><br />
                        1.Stein H, et al. Blood 2000;96:3681–3695.<br /><br />
                        2.WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th Edition.
                        Lyon, France, IARC Press 2008.<br /><br />
                        3.NCCN Non-Hodgkin’s Lymphomas Version1.2011: http://www.nccn.org/professionals
                        /physician_gls/f_guidelines.asp
                        <br /><br />
                        4.Fornarni A, et al. Hematological Oncology 2009;27:161–170
                        <br /><br />
                        5.Falini B, et al. Blood 1999;93:2697–2706.<br /><br />
                    </div>
                </div>
                <!--slide 9 ending-->
                <!--slide 10 starting-->
                <div id="slide10" style="display: none;">
                    <!--<div class="topic-bar">
                        <div id="topic-title">Clinical and Pathological Features of the sALCL Subgroups and Primary Cutaneous ALCL</div>
                    </div>-->
                    <div class="slidecontent" style="">
                        <div class="playBody">
                        <center>
                            <table class="leftbluetable" id="table1" style="width: 630px; display: none;text-align:center; margin-top:20px;">
                                <tr>
                                    <td >
                                        Features</td>
                                    <td style= "text-align:center">
                                        ALK+</td>
                                    <td style= "text-align:center">
                                        ALK-</td>
                                    <td style= "text-align:center">
                                        Primary cutaneous</ br> ALCL</td>
                                </tr>
                                <tr>
                                    <td >
                                        CD30</td>
                                    <td style= "text-align:center">
                                        +</td>
                                    <td style= "text-align:center">
                                        +</td>
                                    <td style= "text-align:center">
                                        +</td>
                                </tr>
                                <tr>
                                    <td >
                                        T-cell phenotype</td>
                                    <td style= "text-align:center">
                                        CD4+/CD8-</td>
                                    <td style= "text-align:center">
                                        CD4+/-/CD8-</td>
                                    <td style= "text-align:center">
                                        CD4+/CD8-</td>
                                </tr>
                                <tr>
                                    <td>
                                        ALK protein</td>
                                    <td style= "text-align:center">
                                        +</td>
                                    <td style= "text-align:center">
                                        -</td>
                                    <td style= "text-align:center">
                                        -</td>
                                </tr>
                                <tr>
                                    <td >
                                        Clusterin</td>
                                    <td style= "text-align:center">
                                        +</td>
                                    <td style= "text-align:center">
                                        +</td>
                                    <td style= "text-align:center">
                                        -</td>
                                </tr>
                                <tr>
                                    <td>
                                        EMA</td>
                                    <td style= "text-align:center">
                                        +</td>
                                    <td style= "text-align:center">
                                        ±</td>
                                    <td style= "text-align:center">
                                        -</td>
                                </tr>
                                <tr>
                                    <td >
                                        Cytotoxic proteins*</td>
                                    <td style= "text-align:center">
                                        +(80%)</td>
                                    <td style= "text-align:center">
                                        +(50%)</td>
                                    <td style= "text-align:center">
                                        +(70%)</td>
                                </tr>
                                <tr>
                                    <td >
                                        Median age, years</td>
                                    <td style= "text-align:center">
                                        <30</td>
                                    <td style= "text-align:center">
                                        >50</td>
                                    <td style= "text-align:center">
                                        >50</td>
                                </tr>
                                <tr>
                                    <td >
                                        Male:Female</td>
                                    <td style= "text-align:center">
                                        M > F</td>
                                    <td style= "text-align:center">
                                        M = F</td>
                                    <td style= "text-align:center">
                                        M > F</td>
                                </tr>
                                <tr>
                                    <td >
                                        5-year survival</td>
                                    <td style= "text-align:center">
                                        65-90%</td>
                                    <td style= "text-align:center">
                                        30-40%</td>
                                    <td style= "text-align:center">
                                        >90%</td>
                                </tr>
                            </table>
                           
                            <div>
                                <p style="display: none; font-size: 12px;  padding-top: 4%;width: 642px;" id="text1">
                                    ALCL = anaplastic large cell lymphoma; ALK = anaplastic lymphoma kinase; EMA = epithelial
                                    membrane antigen; *Cytotoxic proteins = granzyme B, perforin, TIA-1 (T-cell intracytoplasmic
                                    antigen)</p>
                            </div>
                             </center>
                        </div>
                    </div>
                    <!--Transcript -->
                    <div onclick="onclickShowTranscription(this);" id="stickyContent" style="display: none;
                        position: absolute; right: 0; margin-top: 184px;">
                        <a href="#">
                            <img src="../common/img/showTrans.png" /></a>
                    </div>
                    <div id="transcript-hide" style="display: none;">
                        <center>
                            <button type="button" class="hidebutton" onclick="onclickHideTranscription(this);">
                                Hide Transcript</button></center>
                        <div class="transcript">
                            </br><p>
                                This screen shows the clinical and pathological features of the sALCL subgroups
                                and primary cutaneous ALCL.</p>
                            <p>
                                Most cases of sALCL are CD4+.</p>
                            <p>
                                Epithelial membrane antigen and clusterin can be useful diagnostic markers to differentiate
                                cutaneous ALCL from sALCL.<sup>1</sup></p>
                            <p>
                                Other features which help to differentiate the two sALCL subgroups are age, male
                                predominance, and survival rates.</p>
                            <p>
                                This is because ALK- ALCL occurs in older patients (with a peak of incidence in
                                the sixth decade of life).</p>
                            <p>
                                ALK- ALCL also has a lower male predominance and poorer survival when compared to
                                ALK+ ALCL.<sup>2</sup></p>
                        </div>
                    </div>
                    <div id="slide10ref" style="display: none" class="slide10ref">
                        <b>References:</b><br /><br />
                        1. Savage K. Blood Reviews 2007;21:201-216.<br /><br />
                        2. Fornarni A, et al. Hematological Oncology 2009;27:161–170.<br /><br />
                    </div>
                </div>
                <!--slide 10 ending-->
                <div id="slide11" style="display: none;">
                    <!--  <div class="topic-bar">
                    <div id="topic-title">sALCL: Staging and Prognostic Tools</div>
                </div>-->
                    <div class="slidecontent" style="">
                        <div id="bimg1" style="display: none; padding-left: 20px;">
                            <img data-class="fadeInDown" src="../common/img/bullet01.png" style="width: 12px; height: 12px;
                                float: left; margin: 10px; margin-top: 15px;" />
                            <p data-class="fadeInDown" style="padding: 6px">
                                Disease staging is similar to that of other NHLs, and uses the Ann Arbor classification
                                system<sup>1</sup></p>
                        </div>
                        <div id="bimg2" style="display: none; padding-left: 20px;">
                            <img data-class="fadeInDown" src="../common/img/bullet01.png" style="width: 12px; height: 12px;
                                float: left; margin: 10px; margin-top: 15px;" />
                            <p data-class="fadeInDown" style="padding: 6px">
                                The International Prognostic Index (IPI),<sup>2</sup> a standard prognostic model that predicts
                                survival, is used to identify high-risk groups<sup>1</sup></p>
                        </div>
                        <div id="bimg3" style="display: none; padding-left: 20px;">
                            <img data-class="fadeInDown" src="../common/img/bullet01.png" style="width: 12px; height: 12px;
                                float: left; margin: 10px; margin-top: 15px;" />
                            <p data-class="fadeInDown" style="padding: 6px">
                                In the NCCN guidelines for NHLs, patients are stratified into two groups based on
                                an age-adjusted IPI<sup>1</sup></p>
                        </div>
                        <div id="bimg4" style="display: none; padding-left: 20px;">
                            <img data-class="fadeInDown" src="../common/img/bullet01.png" style="width: 12px; height: 12px;
                                float: left; margin: 10px; margin-top: 15px;" />
                            <p data-class="fadeInDown" style="padding: 6px">
                                The NCCN guidelines also recommend the use of the prognosis in T-cell lymphoma (PIT)3
                                scoring system<sup>1</sup></p>
                        </div>
                        <center>
                        <table class="leftbluetable" id="table1" style="display: none; width: 630px;">
                            <tr>
                                <td>
                                    Risk factors</td>
                                <td>
                                    IPI, all patients</td>
                                <td>
                                    PIT risk*</td>
                            </tr>
                            <tr>
                                <td>
                                    > 60 years of age</td>
                                <td>
                                    Low 0 or 1</td>
                                <td>
                                    Group 1 0</td>
                            </tr>
                            <tr>
                                <td>
                                    Serum LDH >1 x normal</td>
                                <td>
                                    Low intermediate 2</td>
                                <td>
                                    Group 2 1</td>
                            </tr>
                            <tr>
                                <td>
                                    Performance status 2-4</td>
                                <td>
                                    High intermediate 3</td>
                                <td>
                                    Group 3 2</td>
                            </tr>
                            <tr>
                                <td>
                                    Stage lll or IV</td>
                                <td>
                                    High 4 or 5</td>
                                <td>
                                    Group 4 3 or 4</td>
                            </tr>
                            <tr>
                                <td>
                                    Extranodal involvement >1 site</td>
                                <td>
                                    High 4 or 5</td>
                                <td>
                                </td>
                            </tr>
                        </table>
                        
                        <div id="text6" style="display: none; padding-left: 20px;">
                            <p style="text-align: center; padding-top: 10px; font-size: 12px; padding-left: 2%;
                                padding-right: 5em;width:640px;">
                                LDH = lacatate dehydogenase;* risk factor = bone marrow involvement instead of Stage
                                lll or IV or extranodal involvement>1 site</p>
                        </div>
                            </center>
                    </div>
                    <div onclick="onclickShowTranscription(this);" id="stickyContent" style="display: none;
                        position: absolute; right: 0; margin-top: 184px;">
                        <a href="#">
                            <img src="../common/img/showTrans.png" /></a>
                    </div>
                    <div id="transcript-hide" style="display: none;">
                        <center>
                            <button type="button" class="hidebutton" onclick="onclickHideTranscription(this);">
                                Hide Transcript</button></center>
                        <div class="transcript" style="">
                            <p>
                                Identifying high-risk groups is of particular importance when evaluating the suitability
                                and the success of a therapeutic intervention.<sup>1,2</sup></p>
                            <p>
                                The disease staging for sALCL is similar to that of other NHLs and uses the Ann
                                Arbor classification system.<sup>1</sup></p>
                            <p>
                                The International Prognostic Index (IPI)<sup>2</sup> is a standard prognostic model
                                that predicts survival and is used to identify high-risk groups.<sup>1</sup></p>
                            <ul>
                                <li><span>The IPI is widely used for adult lymphomas, but has not yet been studied/assessed
                                    in children with lymphomas.<sup>3</sup></span></li>
                            </ul>
                            <p>
                                In the National Comprehensive Cancer Network (NCCN) guidelines for NHLs, patients
                                are stratified into two groups based on an age-adjusted IPI.<sup>1</sup></p>
                            <p>
                                The NCCN guidelines also recommend the use of the prognosis in T-cell lymphoma (PIT)<sup>3</sup>
                                scoring system.<sup>1</sup></p>
                        </div>
                    </div>
                    <div id="slide11ref" style="display: none" class="slide11ref">
                        <b>References:</b><br /><br />
                        1. Savage K, et al. Blood 2008:111:5496–5504.<br /><br />
                        2. Sonnen R, et al. BJH 2005;129:366–372.<br /><br />
                        3.Le Delay M-C, et al. Blood 2008;111:1560–1566.<br /><br />
                    </div>
                </div>
                <!--slide 12 starting-->
                <div id="slide12" style="display: none;">
                    <!--Body -->
                    <!--<div class="topic-bar">
                        <div id="topic-title">sALCL: Survival by Subgroup</div>
                     </div>-->
                    <div class="slidecontent" style="">
                        <div class="playBody">
                            <div id="bimg69" style="display: none; padding-left: 5px;">
                                <img data-class="fadeInRight" src="../common/img/bullet01.png" style="width: 12px; height: 12px;
                                    float: left; margin: 10px;" />
                                <p data-class="fadeInRight" style="padding-left: 32px">
                                    Outcomes are significantly better for patients with ALK+ versus ALK- ALCL<sup>1</sup><sup>-</sup><sup>4</sup>
                                </p>
                            </div>
                            <div id="bimg70" style="display: none; padding-left: 40px;">
                                <img data-class="fadeInRight" src="../common/img/bullet01.png" style="width: 12px; height: 12px;
                                    float: left; margin: 10px;" />
                                <p data-class="fadeInRightBig" style="padding-left: 30px;">
                                    5-year OS: 70&#45;93% for ALK+ ALCL patients<sup>1</sup><sup>-</sup><sup>3</sup></p>
                            </div>
                            <div id="bimg71" style="display: none; padding-left: 40px;">
                                <img data-class="fadeInRight" src="../common/img/bullet01.png" style="width: 12px; height: 12px;
                                    float: left; margin: 10px;" />
                                <p data-class="fadeInRightBig" style="padding-left: 30px;">
                                    5-year OS: 37&#45;49% for ALK- ALCL patients<sup>1</sup><sup>-</sup><sup>3</sup></p>
                            </div>
                            <div id="bimg72" style="display: none; padding-left: 5px;">
                                <img data-class="fadeInRight" src="../common/img/bullet01.png" style="width: 12px; height: 12px;
                                    float: left; margin: 10px;" />
                                <p data-class="fadeInRight" style="padding-left: 34px">
                                    Outcomes in young people (median age 10 years) are similar to those in adults with
                                    ALK+ ALCL
                                </p>
                            </div>
                            <div id="bimg73" style="display: none; padding-left: 40px;">
                                <img data-class="fadeInRight" src="../common/img/bullet01.png" style="width: 12px; height: 12px;
                                    float: left; margin: 10px;" />
                                <p data-class="fadeInRightBig" style="padding-left: 30px;">
                                    5-year OS: 81% (95% CI, 76&#45;86%)</p>
                            </div>
                            <div id="bimg74" style="display: none; padding-left: 40px;">
                                <img data-class="fadeInRight" src="../common/img/bullet01.png" style="width: 12px; height: 12px;
                                    float: left; margin: 10px;" />
                                <p data-class="fadeInRightBig" style="padding-left: 30px;">
                                    5-year progression-free survival: 71% (95% CI, 65&#45;77%)<sup>5</sup></p>
                            </div>
                            <div id="bimgb" style="  display: none; text-align:center;" class="soft-embossed">
                                <img data-class="fadeInRight" src="img/3.png" />
                            </div>
                        </div>
                    </div>
                    <!--Transcript -->
                    <div onclick="onclickShowTranscription(this);" id="stickyContent" style="display: none;
                        position: absolute; right: 0; margin-top: 184px;">
                        <a href="#">
                            <img src="../common/img/showTrans.png" /></a>
                    </div>
                    <div id="transcript-hide" style="display: none;">
                        <center>
                            <button type="button" class="hidebutton" onclick="onclickHideTranscription(this);">
                                Hide Transcript</button></center>
                        <div class="transcript" style="">
                        <p>
                            Outcomes are significantly better for patients with ALK+ versus ALK- ALCL.<sup>1-4</sup>
                            In a paper by Savage et al,
                        </p>
                        <ul>
                            <li><span>The 5-year OS for ALK+ ALCL patients was 70-93%.<sup>1</sup><sup>-</sup><sup>3</sup></span></li>
                            <li><span>The 5-year OS for ALK- ALCL patients was 37-49%.<sup>1</sup><sup>-</sup><sup>3</sup></span></li>
                        </ul>
                        <p>
                            Outcomes in young people (median age 10 years) are similar to those in adults with
                            ALK+ ALCL, with a 5-year OS of 81% (95% CI, 76-86%) and 5-year progression-free
                            survival of 71% (95% CI, 65-77%).<sup>5</sup></p>
                        <p>
                            In the four studies reported here, patients with ALK+ ALCL had significantly better
                            survival rates compared with ALK- ALCL patients, although the ALK+ patients in all
                            four studies were much younger than the ALK- patients.</p>
                        <p>
                            That said, expression of ALK is closely correlated with age and IPI.
                        </p>
                        </div>
                    </div>
                    <div id="slide12ref" style="display: none;" class="slide12ref">
                        <b>References:</b><br /><br />
                        1. Gascoyne R, et al. Blood 1999;93:3913–3921.<br /><br />
                        2.Ten Berge R, et al. Histopathology 2003;43:462–469.<br /><br />
                        3.Savage K, et al. Blood 2008;111:5496–5504.
                        <br /><br />
                        4.Schmitz N, et al. Blood 2010;116:3418–3425.
                        <br /><br />
                        5.Suzuki R, et al. Blood 2000;96:2993&#45;3000.<br /><br />
                    </div>
                </div>
                <!--slide 12 ending-->
         <div id="slide12a" style="display: none;">
                    <!-- <div class="topic-bar">
                        <div id="topic-title">HL: survival rates</div>
                    </div>-->
                    <!--Body -->
                    <div class="slidecontent" style="">
                        <div class="playBody">
                            <div style="padding-left: 20px">
                                <br />
                                <p data-class="fadeInDown" style="display: none;" id="s12atxt1">
                                    Features which help to differentiate the two sALCL subgroups are</p>
                                <br />
                                <input type="hidden" id="Answer" value="4" qid="2" />
                                <input type="hidden" id="Percentage" value="25" />
                                <div id="radio1" style="padding: 10px 25px 10px 10px; display: none;">
                                    <input name="ratio1" value="1" type="radio" style="width: 2em; height: 1.5em; float: left;" />
                                    <p data-class="fadeInRight" style="padding-left: 55px;">
                                        Age</p>
                                </div>
                                <div id="radio2" style="padding: 10px 25px 10px 10px; display: none;">
                                    <input name="ratio1" value="2" type="radio" style="width: 2em; height: 1.5em; float: left;" />
                                    <p data-class="fadeInRight" style="padding-left: 55px;">
                                        Male predominance</p>
                                </div>
                                <div id="radio3" style="padding: 10px 25px 10px 10px; display: none;">
                                    <input name="ratio1" value="3" type="radio" style="width: 2em; height: 1.5em; float: left;" />
                                    <p data-class="fadeInRight" style="padding-left: 55px;">
                                       Immunopositivity for CD30</p>
                                </div>
                                <div id="radio4" style="padding: 10px 25px 10px 10px; display: none;">
                                    <input name="ratio1" value="4" type="radio" style="width: 2em; height: 1.5em; float: left;" />
                                    <p data-class="fadeInRight" style="padding-left: 55px;">Age and Male Predominance</p>
                                </div>
                                
                                <div style="margin-left:470px;">
                                    <div>
                                        <input id="s12aimag9" onclick="onclickAnswer(this);" type="button" class="btn btn-primary" value="Submit"
                                            style="width: 100px; margin-right: 25px; display: none" />
                                    </div>
                                    <br />
                                </div>
                            </div>
                        </div>
                    </div>
                    <!--Transcript -->
                    <div onclick="onclickShowTranscription(this);" id="stickyContent" style="display: none;
                        position: absolute; right: 0; margin-top: 184px;">
                        <a href="#">
                            <img src="../common/img/showTrans.png" /></a>
                    </div>
                    <div id="transcript-hide" style="display: none;">
                        <center>
                            <button type="button" class="hidebutton" onclick="onclickHideTranscription(this);">
                                Hide Transcript</button></center>
                        <div class="transcript">
                            <br />
                            Please take a moment to answer a question. Please select the best answer and click submit to continue

                        </div>
                    </div>
                    <div id="slide6aref" style="display: none;" class="slide6aref">
                        <b>References:</b><br />
                        <br />
                        Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed
                        or Refractory Hodgkin’s Lymphoma. Younes et al. Journal Of Clinical Oncology. June
                        2012.<br /><br />
                    </div>
                </div>
                <!--slide 6a ending-->
                <!--slide 13 starting-->
                <div id="slide13" style="display: none;">
                    <!--Body -->
                    <!--<div class="topic-bar">
                        <div id="topic-title">sALCL: Treatment Overview</div>
                     </div>-->
                    <div class="slidecontent" style="">
                        <div class="playBody">
                            <div id="bimg75" style="display: none; padding-left: 20px;">
                                <br />
                                <img data-class="fadeInRight" src="../common/img/bullet01.png" style="width: 12px; height: 12px;
                                    float: left; margin: 10px;" />
                                <p data-class="fadeInRight" style="padding-left: 34px">
                                    CHOP-based chemotherapy is currently considered the standard first-line treatment<sup>1</sup>
                                </p>
                            </div>
                            <div id="bimg76" style="display: none; padding-left: 20px;">
                                <img data-class="fadeInRight" src="../common/img/bullet01.png" style="width: 12px; height: 12px;
                                    float: left; margin: 10px;" />
                                <p data-class="fadeInRight" style="padding-left: 34px">
                                    CHOP-based chemotherapy is effective in approximately 80% of cases involving children
                                    and 60% of adults with ALK+ ALCL<sup>2</sup>
                                </p>
                            </div>
                            <br />
                            <div id="bimg77" style="display: none; padding-left: 40px;">
                                <img data-class="fadeInRight" src="../common/img/bullet01.png" style="width: 12px; height: 12px;
                                    float: left; margin: 10px;" />
                                <p data-class="fadeInRightBig" style="padding-left: 30px;">
                                    Consolidation with high dose therapy (HDT) followed by autologous stem cell transplant
                                    (ASCT) support is not recommended if patients achieve complete remission<sup>1</sup></p>
                            </div>
                            <br />
                            <div id="bimg78" style="display: none; padding-left: 20px;">
                                <img data-class="fadeInRight" src="../common/img/bullet01.png" style="width: 12px; height: 12px;
                                    float: left; margin: 10px;" />
                                <p data-class="fadeInRight" style="padding-left: 34px">
                                    Patients with ALK- ALCL have a poorer outcome<sup>3</sup>
                                </p>
                            </div>
                            <br />
                            <div id="bimg79" style="display: none; padding-left: 40px;">
                                <img data-class="fadeInRight" src="../common/img/bullet01.png" style="width: 12px; height: 12px;
                                    float: left; margin: 10px;" />
                                <p data-class="fadeInRightBig" style="padding-left: 30px;">
                                    Chemotherapy is effective in approximately 40% of cases<sup>3</sup></p>
                            </div>
                            <div id="bimg80" style="display: none; padding-left: 40px;">
                                <img data-class="fadeInRight" src="../common/img/bullet01.png" style="width: 12px; height: 12px;
                                    float: left; margin: 10px;" />
                                <p data-class="fadeInRightBig" style="padding-left: 30px;">
                                    Consolidation with HDT followed by ASCT is recommended<sup>1</sup></p>
                            </div>
                            <br />
                            <div id="bimg81" style="display: none; padding-left: 20px;">
                                <img data-class="fadeInRight" src="../common/img/bullet01.png" style="width: 12px; height: 12px;
                                    float: left; margin: 10px;" />
                                <p data-class="fadeInRight" style="padding-left: 34px;">
                                    Allogeneic transplantation may be an effective procedure for relapsed or refractory
                                    ALK+ ALCL but its value in the treatment of ALK- ALCL remains to be defined<sup>1</sup></p>
                            </div>
                            <!--<div id="s13text1" style="display: none; padding-left: 20px;">
                                <p data-class="fadeInRight" style="padding-left: 34px;">
                                    CHOP = cyclophosphamide, doxorubicin, vincristine and prednisone
                                </p>
                            </div>-->
                        </div>
                    </div>
                    <!--Transcript -->
                    <div onclick="onclickShowTranscription(this);" id="stickyContent" style="display: none;
                        position: absolute; right: 0; margin-top: 184px;">
                        <a href="#">
                            <img src="../common/img/showTrans.png" /></a>
                    </div>
                    <div id="transcript-hide" style="display: none;">
                        <center>
                            <button type="button" class="hidebutton" onclick="onclickHideTranscription(this);">
                                Hide Transcript</button></center>
                        <div class="transcript" style="">
                            <p>
                                CHOP-based chemotherapy is currently considered the standard first-line treatment
                                for treatment of patients with systemic ALCL.<sup>1</sup></p>
                            <p>
                                It is effective in approximately 80% of cases involving children and 60% of adults
                                with ALK+ ALCL.<sup>2</sup></p>
                            <ul>
                                <li><span>Consolidation with high dose therapy (HDT) followed by autologous stem cell
                                    transplant (ASCT) support is not recommended if patients achieve complete remission.<sup>1</sup></span></li>
                                <li><span>Patients with ALK- ALCL have a poorer outcome.<sup>3</sup></span></li>
                                <li><span>In fact, chemotherapy is effective in approximately 40% of cases<sup>3</sup>
                                    and consolidation with HDT followed by ASCT is recommended.<sup>1</sup></span></li>
                                <li><span>Allogeneic transplantation may be an effective procedure for relapsed or refractory
                                    ALK+ ALCL but its value in the treatment of ALK- ALCL remains to be defined.<sup>1</sup></span></li>
                            </ul>
                            <p>
                                Generally treatment approaches to date have been similar among the PTCL subtypes;
                                however, given the underlying biologic heterogeneity, subtype specific therapies
                                may be more optimal.<sup>1</sup></p>
                        </div>
                    </div>
                    <div id="slide13ref" style="display: none;" class="slide13ref">
                        <b>References:</b><br />
                        <br />
                        1. Savage K, et al. Blood Rev 2007;21:201-216.<br />
                        <br />
                        2. Savage, K. Hematology Am Soc Hematol Educ Program. 2008:280-288.<br />
                        <br />
                        3. Savage K, et al. Blood 2008;111:5496-5504.
                        <br />
                       
                    </div>
                </div>
                <!--slide 13 ending-->
                <div id="slide14" style="display: none;">
                    <!--  <div class="topic-bar">
                    <div id="topic-title">sALCL: Induction Therapy</div>
                </div>-->
                    <div class="slidecontent" style="">
                        <div>
                            <p data-class="fadeInDown" style="display: none; text-align:center; padding-top: 57px;"
                                id="text1">
                                NCCN provides treatment recommendations<sup>1</sup></p>
                           <center> 
                            <table class="leftbluetable" cellspacing="5" cellpadding="5" border="0" class="slide11table"
                                id="table1" style="width: 630px; display: none;">
                                <tr>
                                    <td class="TableHeaderBackground" style="width: 21%; text-align: center">
                                    </td>
                                    <td class="TableHeaderBackground" style="text-align: center">
                                        ALK+ ALCL</td>
                                    <td class="TableHeaderBackground" style="text-align: center">
                                        ALK- ALCL stage l, ll disease and IPI low/low-intermediate</td>
                                    <td class="TableHeaderBackground" style="text-align: center">
                                        ALK- ALCL stage l, ll disease and IPI high/high-intermediate, or stage lll, lV disease</td>
                                </tr>
                                <tr>
                                    <td style=" text-align: left; width: 5%">
                                        Induction therapy</td>
                                    <td>
                                        CHOP plus RT for limited stage disease</td>
                                    <td>
                                        Clinical trial (preferred) or multiagent chemotherapy(4-6 cycles) plus locoregional
                                        RT</td>
                                    <td>
                                        Clinical trial (preferred) or multiagent chemotherapy(6-8 cycles)± RT</td>
                                </tr>
                            </table>
                            
                            <div style="text-align:center;width: 635px;">
                                <p style="display: none; font-size: 12px; padding-left: 4%; padding-top: 3%;" id="text2">
                                    ALCL = anaplastic large cell lymphoma; ALK = anaplastic lymphoma kinase; CHOP =
                                    cyclophosphamide, doxorubicin, vincristine and prednisone; IPI = International Prognostic
                                    Index; RT = radiation therapy</p>
                            </div>
                               </center>
                        </div>
                    </div>
                    <div onclick="onclickShowTranscription(this);" id="stickyContent" style="display: none;
                        position: absolute; right: 0; margin-top: 184px;">
                        <a href="#">
                            <img src="../common/img/showTrans.png" /></a>
                    </div>
                    <div id="transcript-hide" style="display: none;">
                        <center>
                            <button type="button" class="hidebutton" onclick="onclickHideTranscription(this);">
                                Hide Transcript</button></center>
                        <div class="transcript" style="">
                            <p>
                                There are currently no clinical practice or treatment guidelines for ALCL from the:</p>
                            <ul>
                                <li><span>American Society of Hematology</span></li>
                                <li><span>American Society of Clinical Oncology</span></li>
                                <li><span>European Hematology Association</span></li>
                                <li><span>European Society for Medical Oncology</span></li>
                                <li><span>International Conference on Malignant Lymphomas</span></li>
                            </ul>
                            <p>
                                National Comprehensive Cancer Network (NCCN) treatment recommendations are available
                                for ALK+ and ALK- ALCL for:</p>
                            <ul>
                                <li><span>Induction therapy</span></li>
                                <li><span>Follow-up therapy, and</span></li>
                                <li><span>Additional therapy for patients showing a poor response following induction
                                    therapy or for relapsed/refractory ALCL</span></li>
                            </ul>
                        </div>
                    </div>
                    <div id="slide14ref" style="display: none" class="slide14ref">
                        <b>References:</b><br />
                        <br />
                        1. NCCN Non-Hodgkin’s Lymphomas Version1.2014: http://www.nccn.org/professionals
                        /physician_gls/f_guidelines.asp.
                        <br />
                    </div>
                </div>
                <div id="slide15" style="display: none;">
                    <!--  <div class="topic-bar">
                    <div id="topic-title">sALCL: Follow-up and Additional Therapy</div>
                </div>-->
                    <div class="slidecontent" style="">
                        <div id="bimg1" style="display: none; padding-left: 20px; padding-top: 30px;">
                            <img data-class="fadeInRight" src="../common/img/bullet01.png" style="width: 12px; height: 12px;
                                float: left; margin: 8px;" />
                            <p data-class="fadeInRight" style="padding-left: 25px">
                                Follow-up therapy for ALK- ALCL stage l, ll disease, and IPI low/ low-intermediate
                                patients</p>
                        </div>
                        <center>
                        <table class="leftbluetable" border="0" id="table1" style="width: 630px; display: none;">
                            <tr>
                                <td class="TableHeaderBackground" style="width: 20%; text-align: left">
                                </td>
                                <td class="TableHeaderBackground" style="text-align: left; width: 110px;">
                                    Complete response</td>
                                <td class="TableHeaderBackground" style="text-align: left; width: 140px;">
                                    Partial response</td>
                                <td class="TableHeaderBackground" style="text-align: left">
                                    No response or progressive disease</td>
                            </tr>
                            <tr>
                                <td style="text-align: left; width: 5%">
                                    Follow-up therapy</td>
                                <td>
                                    Complete planned course of treatment (RT)</td>
                                <td>
                                    RT or high dose chemotherapy with stem cell rescue or clinical trial</td>
                                <td>
                                    RT or additional therapy as for relapsed/refractory ALCL</td>
                            </tr>
                        </table>
                        </center>
                        <div id="bimg2" style="display: none; padding-left: 20px; padding-top: 66px;">
                            <img data-class="fadeInRight" src="../common/img/bullet01.png" style="width: 12px; height: 12px;
                                float: left; margin: 8px;" />
                            <p data-class="fadeInRight" style="padding-left: 25px">
                               Follow-up therapy for ALK- ALCL stage l, ll IPI high-intermediate/high disease, and  stage III, IV</p>
                        </div>
                        <center>
                        <table class="leftbluetable" id="table2" style="margin-left: 22px; padding-top: 10px;
                            margin-right: 25px; width:630px; display: none;">
                            <tr>
                                <td class="TableHeaderBackground" style="width: 20%; text-align: left">
                                </td>
                                <td class="TableHeaderBackground" style="text-align: left; width: 110px;">
                                    Complete response</td>
                                <td class="TableHeaderBackground" style="text-align: left; width: 140px;">
                                    Partial response</td>
                                <td class="TableHeaderBackground" style="text-align: left">
                                    No response or progressive disease</td>
                            </tr>
                            <tr>
                                <td style="text-align: left; width: 5%">
                                    Follow-up therapy</td>
                                <td>
                                    HDT/ASCT or observation</td>
                                <td colspan="2">
                                    Treated similar to relapsed or refractory disease</td>
                            </tr>
                        </table>
                        </center>
                        <div style="text-align:center;">
                            <p style="display: none; font-size: 12px;padding-top: 3%;" id="text3">
                                ALCL = anaplastic large cell lymphoma; RT = radiation therapy; IPI = International
                                Prognostic Index</p>
                        </div>
                    </div>
                    <div onclick="onclickShowTranscription(this);" id="stickyContent" style="display: none;
                        position: absolute; right: 0; margin-top: 184px;">
                        <a href="#">
                            <img src="../common/img/showTrans.png" /></a>
                    </div>
                    <div id="transcript-hide" style="display: none;">
                        <center>
                            <button type="button" class="hidebutton" onclick="onclickHideTranscription(this);">
                                Hide Transcript</button></center>
                        <div class="transcript" style="">
                            <p>
                                For ALK+ ALCL patients who relapse following induction therapy, additional therapy
                                is recommended.</p>
                          
                            <p>
                               For ALK- ALCL patients with IPI low/low-intermediate stage l,ll disease, following induction therapy interim restaging is recommended. If the PET-CT scan is positive, there should be a rebiopsy before changing course of treatment to follow-up therapy.</p>
                            <ul>
                                <li><span>For patients with complete response completion of the planned RT is recommended
                                    and in those with a partial response RT or high dose chemotherapy with stem cell
                                    rescue or clinical trial is recommended.</span></li>
                                <li><span>For those without a response or with progressive disease, treatment is similar
                                    to that recommended for relapsed or refractory sALCL.</span></li>
                            </ul>
                            <p>
                                For ALK- ALCL patients with IPI high-intermediate/high stage l, ll disease, and
                                stage lll, lV disease, following induction therapy if the PET-CT scan is positive,
                                there should be a rebiopsy before changing treatment course.</p>
                            <ul>
                                <li><span>Those with a complete response in this category can be kept under observation.
                                    Alternatively, they can undergo a HDT/ASCT with local RT before or after the HDT.</span></li>
                            </ul>
                        </div>
                    </div>
                    <div id="slide15ref" style="display: none" class="slide15ref">
                        <b>References:</b><br />
                        1. NCCN Non-Hodgkin’s Lymphomas Version1.2014: http://www.nccn.org/
                           professionals/physician_gls/f_guidelines.asp
                        <br />
                    </div>
                </div>
                <div id="slide15a" style="display: none;">
                    <!--  <div class="topic-bar">
                    <div id="topic-title">sALCL: Follow-up and Additional Therapy</div>
                </div>-->
                    <div class="slidecontent" style="">
                        <div style="text-align: center;">
                            <img data-class="fadeInDown" src="img/sALCL current treatment paradigm.png" id="s15aimg1"
                                style="display: none; width: 666px;height: 245px;margin-top: 20px;" />
                        </div>
                        <div id="s15abimg1" style="display: none; padding-left: 20px; padding-top: 20px;">
                            <img data-class="fadeInRight" src="../common/img/bullet01.png" style="width: 12px; height: 12px;
                                float: left; margin: 10px;" />
                            <p data-class="fadeInRight" style="padding-left: 34px">
                                Additional therapy is recommended for poor response to induction therapy or relapsed/refractory
                                ALCL
                            </p>
                        </div>
                        <center>
                        <table class="leftbluetable" cellspacing="5" cellpadding="5" border="0" class="slide11table"
                            id="s15atable1" style="width: 630px; display: none;">
                            <tr>
                                <td class="TableHeaderBackground" style="width: 30%; text-align: left">
                                </td>
                                <td class="TableHeaderBackground" style="text-align: left">
                                    Candidate for transplant
                                </td>
                                <td class="TableHeaderBackground" style="text-align: left">
                                    Non-candidate for transplant</td>
                            </tr>
                            <tr>
                                <td style="font-weight: bold; text-align: left; width: 5%">
                                    Additional therapy</td>
                                <td style="font-weight: bold;">
                                    Clinical trial or second-line therapy before transplant</td>
                                <td style="font-weight: bold;">
                                    Clinical trial or second-line therapy or palliative RT</td>
                            </tr>
                        </table>
                        
                        <p style="display: none; text-align: center; font-size: 11px;padding-top:10px;" id="s15atext1">
                            ALCL = anaplastic large cell lymphoma; RT = radiation therapy; IPI = International
                             Prognostic Index</p></center>
                    </div>
                    <div onclick="onclickShowTranscription(this);" id="stickyContent" style="display: none;
                        position: absolute; right: 0; margin-top: 184px;">
                        <a href="#">
                            <img src="../common/img/showTrans.png" /></a>
                    </div>
                    <div id="transcript-hide" style="display: none;">
                        <center>
                            <button type="button" class="hidebutton" onclick="onclickHideTranscription(this);">
                                Hide Transcript</button></center>
                        <div class="transcript" style="">
                            <p>
                                Relapse or refractory disease in ALK positive disease despite multi-agent chemotherapy
                                with or without RT requires additional therapy.</p>
                            <p>
                                Additional therapy is also recommended for poor response to induction therapy in
                                ALK negative disease or following progression or relapse after an initial complete
                                response to treatment.</p>
                        </div>
                    </div>
                    <div id="slide15aref" style="display: none" class="slide15aref">
                        <b>References:</b><br />
                        1. NCCN Non-Hodgkin’s Lymphomas Version1.2014: http://www.nccn.org
                          /professionals/physician_gls/f_guidelines.asp
                        <br /><br />
                    </div>
                </div>
                <div id="slide15b" style="display: none;">
                    <!--  <div class="topic-bar">
                    <div id="topic-title">sALCL: Follow-up and Additional Therapy</div>
                </div>-->
                    <div class="slidecontent" style="">
                        <div style="text-align: center;">
                            <img data-class="fadeInDown" src="img/sALCL treatment of relapse or recurrence.png"
                                id="s15bimg1" style="display: none; width: 660px; margin-top: 50px;" />
                        </div>
                        <p class="fadeInDown" id="s15btxt1" style="display: none;font-size: 11px;text-align: center;padding-top: 10px;">
                            *Brentuximab vedotin is recommended after failure of at least one prior multiagent
                            chemotherapy regimen</p>
                    </div>
                    <div onclick="onclickShowTranscription(this);" id="stickyContent" style="display: none;
                        position: absolute; right: 0; margin-top: 184px;">
                        <a href="#">
                            <img src="../common/img/showTrans.png" /></a>
                    </div>
                    <div id="transcript-hide" style="display: none;">
                        <center>
                            <button type="button" class="hidebutton" onclick="onclickHideTranscription(this);">
                                Hide Transcript</button></center>
                        <div class="transcript" style="">
                            <p>
                                Brentuximab vedotin is a treatment option recommended by NCCN for the treatment
                                of recurrent or relapsed sALCL in patients who are not eligible for transplant.</p>
                            <p>
                                Brentuximab vedotin is also recommended for the treatment of relapse/refractory
                                disease in patients who are eligible for transplant; a clinical trial or HDT/ASCT
                                or an allogeneic SCT may be considered after treatment with brentuximab vedotin.</p>
                        </div>
                    </div>
                    <div id="slide15bref" style="display: none" class="slide15bref">
                        <b>References:</b><br />
                        1.NCCN Non-Hodgkin’s Lymphomas Version1.2014: http://www.nccn.org/
                          professionals/physician_gls/f_guidelines.asp
                        <br />
                    </div>
                </div>
                <div id="slide16" style="display: none;">
                    <!--  <div class="topic-bar">
                    <div id="topic-title">NCCN Suggested Treatment Regimens</div>
                </div>-->
                    <div class="slidecontent" style="">
                        <div>
                        <center>
                            <table class="leftbluetable" id="table1" style="width: 630px; display: none; margin-top:20px;">
                                <tr>
                                    <td>
                                        First-line therapy</td>
                                    <td>
                                        Second-line therapy(transplant candidate)</td>
                                    <td>
                                        Second-line therapy(non-transplant candidate)</td>
                                </tr>
                                <tr>
                                    <td>
                                        CHOP21 for ALK+ ALCL</td>
                                    <td>
                                        Brentuximab vedotin</td>
                                    <td>
                                        Alemtuzumab</td>
                                </tr>
                                <tr>
                                    <td>
                                        CHOEP-21 for ALK+ ALCL</td>
                                    <td>
                                        DHAP</td>
                                    <td>
                                        Bortezomib</td>
                                </tr>
                                <tr>
                                    <td>
                                        CHOP- 14</td>
                                    <td>
                                        ESHAP</td>
                                    <td>
                                        Brentuximab vedotin</td>
                                </tr>
                                <tr>
                                    <td>
                                        CHOEP</td>
                                    <td>
                                        GDP</td>
                                    <td>
                                       Dose adjusted EPOCH</td>
                                </tr>
                                <tr>
                                    <td>
                                        CHOP followed by ICE</td>
                                    <td>
                                        GemOx</td>
                                    <td>
                                        Gemcitabine</td>
                                </tr>
                                <tr>
                                    <td>
                                        CHOP followed by IVE</td>
                                    <td>
                                        ICE</td>
                                    <td>
                                        Paralatrexate</td>
                                </tr>
                                <tr>
                                    <td>
                                        Dose adjusted EPOCH</td>
                                    <td>
                                        MINE</td>
                                    <td>
                                        RT</td>
                                </tr>
                                <tr>
                                    <td>
                                        HyperCVAD alternating with high-dose methotrexate and cytarabine </td>
                                    <td>
                                        Paralatrexate</td>
                                    <td>
                                        Romidepsin</td>
                                </tr>
                            </table>
                            
                     
                        <div style="">
                        <p  style="font-size:13px; margin-top:10px;" id=text1><strong>Consolidation therapy with HDT and ASCT may be considered after first-line therapy</strong></p>
                            <p style="display: none; font-size: 12px;width:640px; margin-top: -6px;" id="text2">
                                ALCL = anaplastic large cell lymphoma; ALK = anaplastic lymphoma kinase; CHOP =
                                cyclophosphamide, doxorubicin, vincristine and prednisone; CHOEP = cyclophosphamide,
                                doxorubicin, vincristine, etoposide and prednisone; CVAD = cyclophosphamide, vincristine,
                                doxorubicin, dexamethasone; DHAP = dexamethasone, cisplatin, cytarabine; ESHAP =
                                etoposide, methylprednisolone, cytarabine, cisplatin; GDP = gemcitabine, dexamethasone,
                                cisplatin; GemOx = gemcitabine, oxaliplatin; ICE = ifosfamide, carboplatin, etoposide;
                                IVE = ifosfamide, etoposide and epirubicin; MINE = mesna, ifosfamide, mitoxantronen,
                                etopside; RT = radiation therapy</p>
                        </div>
                        </center>
                               </div>
                    </div>
                    <div onclick="onclickShowTranscription(this);" id="stickyContent" style="display: none;
                        position: absolute; right: 0; margin-top: 184px;">
                        <a href="#">
                            <img src="../common/img/showTrans.png" /></a>
                    </div>
                    <div id="transcript-hide" style="display: none;">
                        <center>
                            <button type="button" class="hidebutton" onclick="onclickHideTranscription(this);">
                                Hide Transcript</button></center>
                        <div class="transcript" style="">
                            <p>
                                NCCN has suggested treatment regimens for first-line therapy, second-line therapy
                                in transplant candidates, and second-line therapy in patients who are not candidates
                                for transplant.</p>
                            <ul>
                                <li><span>This screen shows a variety of first and second-line treatment regimens</span></li>
                            </ul>
                            <p>
                                Additionally, standard induction for PTCL remains undefined with the exception of
                                ALK+ ALCL, for which CHOP remains the standard. Clinical trials are preferred for
                                all other subtypes of PTCL including ALK- ALCL.</p>
                            <p>
                                First-line consolidation is recommended for all patients except those with low risk
                                IPI where consolidation with high dose therapy and stem cell rescue is recommended.</p>
                            <p>
                                ALK+ ALCL does not need consolidative transplant if the patient is in remission.</p>
                            <p>
                                Activity has been demonstrated with alemtuzumab in small clinical trials.</p>
                            <p>
                                The NCCN notes that there is a need for additional/larger trials to confirm the
                                activity of alemtuzumab.</p>
                        </div>
                    </div>
                    <div id="slide16ref" style="display: none" class="slide16ref">
                        <b>References:</b><br />
                        <br />
                          1. NCCN Non-Hodgkin’s Lymphomas Version1.2011: http://www.nccn.org/professionals /physician_gls/f_guidelines.asp
                        <br />
                        <br />
                    </div>
                </div>
                <div id="slide17" style="display: none;">
				
                    <!--  <div class="topic-bar">
                    <div id="topic-title">Knowledge Check</div>
                </div>-->
                    <div class="slidecontent" style="">
                        <div class="playBody">
                            <div style="padding-left: 20px">
                                <br />
                                <p data-class="fadeInDown" style="display: none;" id="text1">
                                    What is the standard first-line treatment for sALCL?</p>
                                <br />
                                <input type="hidden" id="Answer" value="2" qid="3" />
                                        <input type="hidden" id="Percentage" value="25" />
                                <div id="radio1" style="padding: 10px 25px 10px 10px; display: none;">
                                    <input name="ratio1" value="1" type="radio" style="width: 2em; height: 1.5em; float: left;" />
                                    <p data-class="fadeInRight" style="padding-left: 55px;">
                                       Allogeneic transplantation</p>
                                </div>
                                <div id="radio2" style="padding: 10px 25px 10px 10px; display: none;">
                                    <input name="ratio1" value="2" type="radio" style="width: 2em; height: 1.5em; float: left;" />
                                    <p data-class="fadeInRight" style="padding-left: 55px;">CHOP-based chemotherapy</p>
                                </div>
                                <div id="radio3" style="padding: 10px 25px 10px 10px; display: none;">
                                    <input name="ratio1" value="3" type="radio" style="width: 2em; height: 1.5em; float: left;" />
                                    <p data-class="fadeInRight" style="padding-left: 55px;">
                                        Locoregional RT</p>
                                </div>
                                <div id="radio4" style="padding: 10px 25px 10px 10px; display: none;">
                                    <input name="ratio1" value="4" type="radio" style="width: 2em; height: 1.5em; float: left;" />
                                    <p data-class="fadeInRight" style="padding-left: 55px;">
                                         ABVD</p>
                                </div>
                                <div style="margin-left:470px;">
                                    <div>
                                        <input id="button1" onclick="onclickAnswer(this);" type="button" class="btn btn-primary" value="Submit" style="width: 100px;
                                            margin-right: 25px; display: none" />
                                    </div>
                                    <br />
                                </div>
                            </div>
                        </div>
                    </div>
                    <div onclick="onclickShowTranscription(this);" id="stickyContent" style="display: none;
                        position: absolute; right: 0; margin-top: 184px;">
                        <a href="#">
                            <img src="../common/img/showTrans.png" /></a>
                    </div>
                    <div id="transcript-hide" style="display: none;">
                        <center>
                            <button type="button" class="hidebutton" onclick="onclickHideTranscription(this);">
                                Hide Transcript</button></center>
                        <div class="transcript" style="">
                            <p>
                             Please take a moment to answer a question. Please select the best answer and click submit to continue</div>
                    </div>
                    <div id="slide17ref" style="display: none" class="slide17ref">
                        <b>No References:</b><br />
                        <br />
                    </div>
                </div>
            
         
		        <div id="slide18" style="display: none;">
				
                    <!-- <div class="topic-bar">
                        <div id="topic-title">Title</div>
                    </div>-->
                    <!--Body -->

                    <div style="height: 550px;width: 100%;margin:0px auto; border: 2px solid rgba(127, 145, 145, 0.12);border-radius: 10px;background-color: rgba(255, 255, 255, 0.2);">
                        <div class="playBody">
                            <div data-class="fadeInDown" class="breakout" style="display: none;text-align:center;height:95px;"  id="s18img1">
                                <p class="" style="font-size: 20px;width:450px;position:relative;text-align:left">
                                    End of Module!
                                </p>
								<p class="fadeInDown" id="s18img2" style="display: none;text-align:left"> Please close the window and attempt the post-test in order to complete the course.</p>	
							    
                            </div>
                        </div>
                    </div>
			</div>
        </div>
      
            
     </div>
    </div>
		
		
  
    <div id="footer" style="width: 1024px; margin: 0 auto;">
        <div class="container" style="">
            <table style="width: 100%">
                <tr>
                    <td>
                        <img src="../common/img/takeda.png" style="float: left; width: 105px; margin-top: 3px; margin-right: 10px;
                            margin-left: -25px;" />
                    </td>
                    <td>
                        <img onmouseover="HideToolTip(this)" data-toggle="tooltip" title="Play / Pause" class="effect"
                            id="toggelbutton" class="effect" src="../common/img/playBtn.png" style="float: left; margin-top: -10px;"
                            onclick="play()" />
                    </td>
                    <td>
                        <div style="float: left;">
                            <input id="progress-bar" type="text" data-slider="true" data-slider-highlight="true">
                            <div class="slider-control">
                                <span id="slideCount">Frame 0 of 00</span> <span style="float: right;"><span id="timeduration">
                                    0:00</span> / <span id="slideduration">0:00</span></span>
                            </div>
                        </div>
                    </td>
                    <td>
                        <img onmouseover="HideToolTip(this)" data-toggle="tooltip" data-placement="left"
                            title="Previous Slide " class="effect" src="../common/img/prevBtn.png" style="margin-top: -10px;"
                            onclick="Prev()" />
                    </td>
                    <td>
                        <img onmouseover="HideToolTip(this)" id="NxtImg" data-toggle="tooltip" title="Next Slide" class="effect"
                            src="../common/img/nxtBtn.png" style="margin-top: -10px;" onclick="Next()" />
                    </td>
                    <td>
                        <img onclick="ShowHelp(); " id="showHelp" src="../common/img/smallicon2.png" style="margin-top: -10px;
                            margin-left: 35px;" />
                    </td>
                    <td>
                        <a href="pdf/Transcript.pdf" target="_blank">
                            <img onmouseover="HideToolTip(this)" data-toggle="tooltip" title="Print" class="effect"
                                src="../common/img/smallicon3.png" style="margin-top: -10px;" /></a>
                    </td>
                </tr>
            </table>
            <!--  <img class="effect" src="../common/img/pauseBtn.png" style="float: left; margin-top: -10px;" onclick="pause()" />-->
        </div>
    </div>

    <div class="modal fade" id="AnswerModal" data-backdrop="static" tabindex="-1" role="dialog"
        aria-labelledby="myModalLabel" aria-hidden="true">
        <div class="modal-dialog">
            <div class="modal-content">
                <div class="modal-body">
                </div>
                <div class="modal-footer">
                    <button type="button" onclick="onclickAnswerContinue()" class="btn btn-primary">
                        Continue</button>
                </div>
            </div>
        </div>
    </div>

    <script>
        $('img').tooltip({ trigger: "focus" });

    </script>

</body>
</html>
